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Abstract 
The Study was a Case Control undertaken to understand the etiology of esophageal 
cancer in the population of Kashmiri origin. This case control study was designed to 
assess the relationship of promoter hypermethylation of Mismatch Repair Gene MutL 
homolog 1 (hMLH1) with esophageal cancer. Also further an association of 
hypermethylation of hMLH1 gene with esophageal cancer in relation to 
clinicopathological features of Gender and Age was evaluated. 
Esophageal cancers are one of the most fatal cancers in the world and are 
considered to be the eighth most common malignancy. The prognosis of Esophageal Cancer 
is poor as its symptoms appear in the late stage of the disease. This cancer is one of the 
most prevalent cancers in Jammu and Kashmir region of India and has multi-factorial 
etiology involving dietary habits, genetic factors, and gene environmental interactions. 
Genetic abnormalities of proto-oncogenes, tumor suppressor genes and mis-match repair 
genes have been demonstrated to be involved frequently in esophageal carcinogenesis; 
chronic inflammation leading to malignancy in the esophagus may be due to errors in 
mismatch repair (MMR) genes such as hMLH1. Inactivation of the hMLH1 gene 
expression by aberrant promoter methylation plays an important role in the progression of 
esophageal carcinoma. In the present study the role of hMLH1 promoter methylation in 
50 histopathologically confirmed esophageal cancer tissues and compared it with 
corresponding histopathologically confirmed Normal adjacent tissues was studied by 
methylation-specific polymerase chain reaction (MS-PCR). 
For evaluating the status of hMLH1 promoter hypermethylation and its 
association with Esophageal Cancer, a methylation specific polymerase chain reaction 
(MS-PCR) was used. DNA was extracted and treated with sodium bisulfite which 
converts unmethylated cytosines to uracil and does not affect methylated cytosines. The 
modified DNA was amplified in MS-PCR reaction by applying methylated and 
unmethylated promoter specific primers. Universally methylated DNA was used as 
positive control and DNA from normal lymphocytes used as negative control. The MS-
PCR products were run on 3% agarose and bands were visualized under UV light.  
      
 
 
It was found that the frequency of promoter region hypermethylation of mismatch 
repair gene (hMLH1) in esophageal cancer cases was 56% (28 out of 50) and in 
histopathologically confirmed normals it was 15% (03 out of 20).Statistically the 
association of promoter region hypermethylation of mismatch repair gene (hMLH1) with 
esophageal cancer was evaluated using χ2-test (chi-square test) with odds ratio and was 
found significant and the p<0.05. It was also found that the methylation status of 
MutL homolog 1 (hMLH1) gene in esophageal cancer cases was high in Males (60%) 
compared to Females (47%) and in Controls, Males (16%) also shows high with respect to 
Females (12%) which shows insignificant association as  p>0.05.From the data it was 
concluded that The Frequency of MutL homolog 1 (hMLH1) gene promoter region 
hypermethylation was found high in Esophageal Cancer Cases of above 40 years of age 
(56%) and in controls (16%) and was significant as p<0.05 compared to below 40 years of 
age (50%) and in controls (0%) and association was insignificant as p>0.05 and was 
evaluated by Fishers exact test. 
Observing similar level of hMLH1 promoter hypermethylation in patients with 
Esophageal Cancer in this high risk region and comparing it with other parts of the world 
could support the hypothesis that a common molecular mechanism might be involved in 
tumorigenesis of Esophageal Cancer. As regards promoter hypermethylation status of 
mismatch repair gene hMLH1 shows a significant increase in promoter region 
hypermethylation of esophageal cancer patients of Kashmiri origin as compared to 
controls was observed. This became more apparent when the data for hypermethylation  
was interpreted taking Gender into consideration here it was seen that Males shows 
higher frequency of promoter region hypermethylation as compared to females which was 
earlier reported in literature and also patients of above 40 years of age shows high 
frequency compared to below 40 years of age. 
 
  
      
 
 
1.1 Introduction to Cancer 
Cancer is the uncontrolled growth of abnormal cells anywhere in a body. The 
abnormal cells are termed cancer cells, malignant cells, or tumor cells. Cancer (medical term: 
malignant neoplasm) is a class of diseases in which a group of cells display: 
 Uncontrolled Growth 
 Invasion that intrudes upon and destroys adjacent tissues and 
 Sometimes Metastasis or Spreading to other locations in the body via lymph or blood. 
These three malignant properties of cancers differentiate them from benign tumors, 
which do not invade or metastasize. Cancer occurs when a cell's gene mutations make the cell 
unable to correct DNA damage and unable to commit suicide. Similarly, cancer is a result of 
mutations that inhibit oncogene and tumor suppressor gene function, leading to 
uncontrollable cell growth. All cancers begin in cells, the body's basic unit of life. These cells 
grow and divide in a controlled way to produce more cells as they are needed to keep the 
body healthy. When cells become old or damaged, they die and are replaced with new cells. 
However; sometimes this orderly process goes wrong. The genetic material (DNA) of a cell 
can become damaged or changed, producing mutations that affect normal cell growth and 
division. When this happens, cells do not die when they should and new cells form when the 
body does not need them. The extra cells may form a mass of tissue called a Tumor (Figure 
1).Cancer is currently the cause of 12% of all deaths worldwide. In approximately 20 years’ 
time, the number of cancer deaths annually will increase from about 6 million to 10 million. 
The principal factors contributing to this projected increase are the increasing proportion of 
elderly people in the world (in whom cancer occurs more frequently than in the young), an 
overall decrease in deaths from communicable diseases, the decline in some countries in 
mortality from cardiovascular diseases, and the rising incidence of certain forms of cancer, 
notably lung cancer resulting from tobacco use (National Cancer Control Programmes, 2002). 
Cancer prevalence in India is estimated to be around 2.5 million, with over 8, 00,000 new 
cases and 5,50,000deaths occurring each year due to this disease in the country (Nandakumar, 
1996).Cancer is a complex disease characterized by multiple genetic and epigenetic genomic 
alterations (Jones and Baylin, 2002; Feinberg et.al., 2006;Esteller, 2007).Many cancers and 
the abnormal cells that compose the cancer tissue are further identified by the name of the 
tissue that the abnormal cells originated from for example: 
      
 
 
 Breast Cancer 
  Colon Cancer 
 Lung Cancer 
 EsophagealCancer etc. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Loss of normal growth control in cancer cells.  
 
(Source- National Cancer Institute) 
 
      
 
 
1.2 Introduction toEsophageal Cancer (EC) 
Esophageal cancer (or oesophageal cancer) is malignancy of the esophagus. 
Esophageal cancers are typically carcinomas which arise from the epithelium, or surface 
lining, of the esophagus (Esophageal cancer, Mount Sinai Hospital).Esophageal cancer is a 
relatively rare form of cancer, but some world areas have a markedly higher incidence than 
others: Belgium, China, Iran, Iceland, India, Japan, the United Kingdom, appear to have a 
higher incidence, as well as the region around the Caspian Sea (Stewart et al., 2003). 
Esophageal cancer ranks sixth among all cancers worldwide, with 400 000 new cases being 
diagnosed per year. This cancer is the eighth most commonly occurring cancer and the sixth 
most common cause of cancer death in the world. It occurs most often in men over 50 years 
old. This malignancy exists in two principal forms, each possessing distinct pathological 
characteristics: Esophageal squamous cell carcinoma (ESCC), which occurs at high 
frequencies in many developing countries, particularly in Asia, and Esophageal 
adenocarcinoma (EAC), which is more prevalent in Western countries, with a rapid rate of 
increase in recent years (Stewart et al., 2003)(Figure 2). A general rule of thumb is that a 
cancer in the upper two-thirds is a squamous cell carcinoma and one in the lower one-third is 
a adenocarcinoma. Rare histologic types of esophageal cancer are different variants of the 
squamous cell carcinoma, and non-epithelial tumors, such as leiomyosarcoma, malignant 
melanoma, rhabdomyosarcoma, lymphoma and others (Shield et al., 2005; Halperinet al., 
2008). 
Prognosis depends on the extent of the disease and other medical problems, but is 
fairly poor, because most patients present with advanced disease. By the time the first 
symptoms such as dysphagia start manifesting themselves, the cancer has already well 
progressed. The overall five-year survival rate (5YSR) is approximately 15%, with most 
patients dying within the first year of diagnosis (Polednak, 2003). Staging is a careful attempt 
to find out whether the cancer has spread and, if so, to what parts of the body. Knowing the 
stage of the disease helps the doctor plan treatment. Listed below are descriptions of the four 
stages of esophageal cancer.  
 Stage I. The cancer is found only in the top layers of cells lining the esophagus.  
 Stage II. The cancer involves deeper layers of the lining of the esophagus, or it has 
spread to nearby lymph nodes. The cancer has not spread to other parts of the body.  
      
 
 
 Stage III. The cancer has invaded more deeply into the wall of the esophagus or has 
spread to tissues or lymph nodes near the esophagus. It has not spread to other parts of 
the body.  
 Stage IV. The cancer has spread to other parts of the body. 
Esophageal cancer can spread almost anywhere in the body, including the liver, lungs, 
brain, and bones.Esophageal carcinoma (EC) is one of the most common cancer occurring 
globally (Parkinet al., 2005) and is a major cause of cancer related deaths in India. The high 
incidence areas in India includes North-East India (Phukanet al., 2001) and Kashmir valley 
(Khurooet al., 1992) where environment and dietary habits play an overwhelming role in the 
development of EC over the genetic factors. The main cause appears to be a combination of 
environmental, dietary and genetic factors. Kashmir is one of the three provinces (Jammu, 
Kashmir, and Ladakh) of the Jammu and Kashmir state. There is high incidence of 
gastrointestinal malignancies in general and esophageal cancer in particular in Kashmir 
valley and constitute more than 15% of all cancer cases in Kashmir. The valley is considered 
a part of “Esophageal cancer belt” in Asia and has unique socio-cultural and dietary features 
that make it a very intriguing region for studying this disease. The annual incidence of 
esophageal cancer in Kashmir is reported as 42 and 27 for men and women, respectively per 
100,000 individuals (Khurooet al., 1992).In Kashmir a lot of dietary features and life style are 
peculiar, e.g., consumption of hot salted tea, sun-dried vegetables of Brassica family (Hakh), 
pickled vegetables (Anchar), dried fish, red chilies, spice cakes etc. These food items have 
been found to contain substantial amount of N-nitroso compounds including N-
nitrosopipecolic acid, mono and diamines of methane and ethane, with several unidentified 
nonvolatile N-nitroso compounds (Kumaret al., 1992; Siddiqiet al., 1992, 1998). 
Gastrointestinal (GI) cancers account for about 20% of all cancers worldwide. In the 
global incidence of cancer, gastric cancer is the second, colorectal cancer is the third, and 
esophageal cancer is the sixth most common tumor (Chan and Rashid, 2006).In neoplasms, 
including GI cancers, epigenetic changes play a key role in the process of  tumorigenesis 
(Baylin , 2002, 2006). 
 
 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Endoscopic image of patient with esophageal 
adenocarcinoma seen at gastro-esophageal 
junction 
 
(Source: Esophageal cancer Wikipedia) 
      
 
 
1.3 Introduction to Epigenetics 
The term epigenetic refers to information which is transmitted from the parental 
genome to the next generation of cells which is not encoded by the primary DNA sequence. 
Epigenetic mechanisms are essential for the regulation of gene expression and genome 
integrity in normal cells (for reviews see (Bird, 2002; Li, 2002; Jaenisch and Bird 2003). 
Epigenetic information is often transmitted by methylation of the 5 carbon position of 
cytosine within a CpG dinucleotide, also referred to as DNA methylation. CpG dinucleotides 
are under-represented in the genome, but over-represented in short regions of 500– 4,000 bp 
(base pair) in length, known as CpG islands, which are rich in CpG content (Bird, 2002; 
Takai and Jones 2002). CpG islands are present in the proximal promoter regions of about 
60% of the genes in the mammalian genome and are, generally, unmethylated in normal cells. 
Patterns of DNA methylation and chromatin structureare profoundly altered in neoplasia and 
include genome wide losses of and regional gains in DNA methylation (Feinberg and 
Vogelstein 1983).Global hypomethylation was shown to cause genomic instability which in 
turn may promote secondary genetic alterations (Eden et al., 2003; Gaudetet al., 2003), 
whereas local hypermethylation of promoter regions is associated with transcriptional 
silencing and can lead to the loss of tumor-suppressor gene function. The molecular 
mechanisms of epigenetic silencing during tumor formation are only partially understood. In 
normal cells the pattern of CpG methylation is brought about by a group of enzymes known 
as the DNA methyltransferases (DNMT). The DNMTs known to date are DNMT1, 
DNMT1b, DNMT1o, DNMT1p, DNMT2, DNMT3A, DNMT3b with its isoforms and 
DNMT3L (Robertson et al., 2002). Methylation can be de novo (when CpG dinucleotides on 
both DNA strands are unmethylated) or maintenance (when CpG dinucleotides on one strand 
are methylated). DNMT1 has de novo as well as maintenance methyltransferase activity, and 
DNMT3A and DNMT3b are powerful de novo methyltransferases (Marzoet al., 1999; 
Robertson et al., 2000; Costello and Plass 2001). Methylation of various biological molecules 
including DNA is dependent on S-adenosylmethionine (SAM), the principal biological 
methyl group donor (Stern et al., 2000; Yi et al., 2000). Considering the critical role of 
methylation in various cellular processes, it is understandable that any alteration in the 
availability of SAM may have a profound effect on cellular growth, differentiation and 
function in both health and illness. Methylenetetrahydrofolate reductase (MTHFR), a rate-
limiting enzyme in the conversion of homocysteine to methionine, which is the substrate for 
      
 
 
SAM, may play a regulatory role in the folate metabolism and methylation process 
(Bolander, 2002). 
Elevated homocysteine levels, either due to MTHFR mutation or a diet deficient in 
cofactors for the methylation cycle, result in the formation of S-adenosyl L-homocysteine, 
which is a competitive inhibitor of SAM. This, as a result, affects methylation in various 
biological processes (Figure 3). 
CpG islands, frequently located at the 5'-end regulatory regions of genes, are subject 
to epigenetic modifications including DNA methylation and histone modification that are 
known to play an important role in regulating gene expression (Jones and Baylin 2002). In 
normal cells, the majority of promoter CpG islands are protected from this epigenetic event 
and thus they are unmethylated. Conversely, in cancer cells, several promoter CpG islands 
are hypermethylated and form a closed repressive chromatin configuration that affects the 
transcription initiation of the corresponding genes (Estelleret al., 2001,2002; Baylin, 2006). 
Reports of hypermethylation in cancer far outnumber the reports of hypomethylation 
in cancer. There are several protective mechanisms that prevent the hypermethylation of the 
CpG islands. These include active transcription, active demethylation, replication timing, and 
local chromatin structure preventing access to the DNA methyltransferase (Clark and Melki 
2002). 
To date, nearly 50% of numerous genes have been found to undergo 
hypermethylation in cancer. The genes that are susceptible are: 
 The genes involved in cell cycle regulation (p16INK4a, p15INK4a, Rb, p14ARF) 
 The genes associated with DNA repair (hMLH1,BRCA1, MGMT) 
 The genes involved in apoptosis (DAPK, TMS1) 
 The genes associated with angiogenesis (THBS1, VHL) 
 The genes involved in invasion (CDH1, TIMP3) 
 The genes involved in drug resistance, detoxification, differentiation, and metastasis 
(Jones and Baylin 2002). 
 
 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3:Cytosine gets converted into 5'methyl cytosine by the action of S-
adenosylmethionine (SAM) which donates methyl groups and is 
converted to S-adenosylhomocysteine (SAH) in presence of 
DNMTs. 
 
(Source: Review article on role of methylation) 
      
 
 
1.4 Introduction to hMLH1Gene 
The DNA mismatch repair (MMR) protein hMLH1 is encoded by the MutL homolog 
1 (hMLH1) gene in humans and is a homologue of the DNA MMR gene mutL of Escherichia 
coli (Figure 4). The MMR function is associated with DNA replication, to correct for 
deficiencies in DNA polymerase proofreading function. A missing gene or mutations of this 
gene and other MMR genes (MSH2, MSH6, or PMS2) leads to microsatellite instability 
(MSI) and this dysfunction is highly associated with hereditary non-polyposis colon cancer 
(HNPCC or Lynch syndrome) (Bronneret al., 1994).The hMLH1 gene provides instructions 
for making a protein that plays an essential role in DNA repair. This protein fixes mistakes 
that are made when DNA is copied (DNA replication) in preparation for cell division. The 
hMLH1 protein joins with another protein, the PMS2 protein, to form an active protein 
complex. This protein complex coordinates the activities of other proteins that repair 
mistakes made during DNA replication. The repairs are made by removing a section of DNA 
that contains mistakes and replacing the section with a corrected DNA sequence (Jascur and 
Boland 2006).Human MutL homologue or hMLH1 is a member of the mismatch repair 
system whose function is to replicate the genome faithfully (Ahujaet.al., 1998). Deficiencies 
in this system result in mutation rates 100-fold higher than those observed in normal cells 
(Thomaset al., 1996; Jiricny, 2006). 
The Study was a Case Control undertaken to understand the etiology of esophageal 
cancer in the population of Kashmiri origin. The hypermethylation of the promoter region of 
mismatch repair gene hMLH1 was not well documented in esophageal cancer population of 
Kashmiri origin. So this study was confined to study the promoter region hypermethylation of 
hMLH1 gene in esophageal cancer population of Kashmiri origin. In this study a candidate 
gene approach was used to study a key cancer gene (hMLH1) undergoing epigenetic 
inactivation in esophageal cancer. In this study, it was demonstrated how one single type of 
DNA alteration, aberrant methylation of gene promoter, can point to pathway disrupted in 
esophageal cancer. Also further an association of hypermethylation of hMLH1gene with 
esophageal cancer in relation to clinicopathological features was evaluated as Gender and 
Age. 
 
 
      
 
 
 
 
 
  
Figure 4:Location of hMLH1 gene on short p arm of 
chromosome 3 
 
(Source: Handbook Genetics home reference) 
      
 
 
REVIEW OF LITERATURE: 
2.1 Literature about General Cancer 
The body is made up of many types of cells. These cells grow and divide in a 
controlled way to produce more cells as they are needed to keep the body healthy. When cells 
become old or damaged, they die and are replaced with new cells. However, sometimes this 
orderly process goes wrong. The genetic material (DNA) of a cell can become damaged or 
changed, producing mutations that affect normal cell growth and division. When this 
happens, cells do not die when they should and new cells form when the body does not need 
them. The extra cells may form a mass of tissue called a tumor. Cancer (medical term: 
malignant neoplasm) is a class of diseases in which a group of cells display uncontrolled 
growth, invasion that intrudes upon and destroys adjacent tissues, and sometimes metastasis, 
or spreading to other locations in the body via lymph or blood. These three malignant 
properties of cancers differentiate them from benign tumors, which do not invade or 
metastasize. Cells can experience uncontrolled growth if there are damages or mutations to 
DNA, and therefore, damage to the genes involved in cell division. Four key types of gene 
are responsible for the cell division process: oncogenes tell cells when to divide, tumor 
suppressor genes tell cells when not to divide, suicide genes control apoptosis and tell the cell 
to kill itself if something goes wrong, and DNA-repair genes instruct a cell to repair damaged 
DNA. Cancer occurs when a cell's gene mutations make the cell unable to correct DNA 
damage and unable to commit suicide. Similarly, cancer is a result of mutations that inhibit 
oncogene and tumor suppressor gene function, leading to uncontrollable cell growth. All 
cancers begin in cells, the body's basic unit of life. These cells grow and divide in a 
controlled way to produce more cells as they are needed to keep the body healthy. When cells 
become old or damaged, they die and are replaced with new cells. However, sometimes this 
orderly process goes wrong. The genetic material (DNA) of a cell can become damaged or 
changed, producing mutations that affect normal cell growth and division. When this 
happens, cells do not die when they should and new cells form when the body does not need 
them. The extra cells may form a mass of tissue called a Tumor. 
Cancer is currently the cause of 12% of all deaths worldwide. In approximately 20 
years’ time, the number of cancer deaths annually will increase from about 6 million to 10 
million. The principal factors contributing to this projected increase are the increasing 
proportion of elderly people in the world (in whom cancer occurs more frequently than in the 
      
 
 
young), an overall decrease in deaths from communicable diseases, the decline in some 
countries in mortality from cardiovascular diseases, and the rising incidence of certain forms 
of cancer, notably lung cancer resulting from tobacco use (National Cancer Control 
Programme 2002).Of the 10 million new cancer cases seen each year worldwide, 4.7 million 
are in the more developed countries and nearly 5.5 million are in the less developed 
countries. Although the disease has often been regarded principally as a problem of the 
developed world, more than half of all cancers occur in the developing countries. In 
developed countries, cancer is the second most common cause of death, and epidemiological 
evidence points to the emergence of a similar trend in developing countries (Stewart and 
Kleihues 2003).Cancer prevalence in India is estimated to be around 2.5 million, with over 
8,00,000 new cases and 5,50,000 deaths occurring each year due to this disease in the country 
(Nandakumar, 1996).Cancer is a complex disease characterized by multiple genetic and 
epigenetic genomic alterations (Jones and Baylin 2002; Feinberg et.al., 2006; Esteller, 2007). 
DNA methylation is one of the most important epigenetic alterations and plays a critical 
functional role in development, differentiation and diseases (Jones and Baylin 2002). 
Through the activity of DNA methyltransferases (DNMTs), DNA methylation occurs at the 
cytosine residue in the context of 5'-CG-3' (CpG dinucleotide) across human genome (Laird, 
2003). During the developmental process, DNA methylation plays an essential role in X 
chromosome inactivation in female somatic cells and in the mono-allelic silencing of 
parentally imprinted genes. Once these DNA methylation patterns are acquired in the early 
embryo stage, these patterns are inherited and maintained in successive cell generations. 
Promoter regions are usually enriched with CpG dinucleotides, known as CpG islands; and 
hypermethylation of these islands correlates with transcriptional silencing of corresponding 
genes (Herman and Baylin 2003). 
2.2 Literature about Esophageal Cancer (EC) 
Esophageal cancers are one of the most fatal cancers in the world and are considered 
to be the eighth most common malignancy (Parkin et al., 2005). The prognosis of EC is poor 
as its symptoms appear in the late stage of the disease. Also, the treatment of EC is 
protracted, decreases the quality of life and is lethal in significant number of cases, making it 
the seventh leading cause of death from cancer (Parkin et al., 2005). There are two main 
histological types of esophageal cancer; squamous cell carcinoma (SCC) and adenocarcinoma 
(ADC). Squamous cell carcinoma of the esophagus remains predominantly a disease of the 
      
 
 
developing world and adenocarcinoma a disease of western developed societies, associated 
with obesity and gastro-esophageal reflux disease (GERD). Esophageal cancer is more 
frequent in men as compared to women (Parkin et al., 2005).Approximately 11,000 to 13,000 
new cases of esophageal cancer are diagnosed each year in the United States alone. Hospital-
based data on cancer from India indicate that esophageal cancer ranks third in males and 
fourth in females (Chitra et al., 2004). Genetic, epigenetic and environmental factors 
including diet have been implicated in the causation of this cancer (Mayne et al., 2001; Yang 
et al., 2005). The esophagus is a 25-cm-long muscular tube of the digestive tract carrying 
food from the mouth to the stomach. Patients present with symptoms that include dyspepsia, 
dysphagia and regurgitation. Chronic injury or irritation and inflammation to the esophagus 
can arise due to chronic infection, drug use, ingestion of corrosive chemicals, idiopathic or 
allergic causes, alcohol consumption, smoking, tobacco chewing and tea and coffee 
consumption (Kim et al., 1997; Vaughan et al., 1998; Li and Yu 2003). More than 30% of the 
adult population suffers from esophageal disorders like esophagitis, reflux esophagitis due to 
gastroesophageal reflux disease (GERD), etc (Rosai, 1996). GERD caused by the upward 
backflow of stomach acid, bile, pepsin, ingested liquids and foods into the esophagus results 
in reflux esophagitis. Apart from precancerous lesions like hyperplasia, dysplasia and 
carcinoma in situ, Barrett’s esophagus is another inflammatory, premalignant condition of the 
esophagus, primarily seen to be associated with GERD (Bani et al., 2000; Kagawa et al., 
2000).Esophageal cancer is a relatively rare form of cancer, but some world areas have a 
markedly higher incidence than others: Belgium, China, Iran, Iceland, India, Japan, the 
United Kingdom, appear to have a higher incidence, as well as the region around the Caspian 
Sea (Stewart and Kleihues 2003). The American Cancer Society estimates that during 2007, 
approximately 15,560 new esophageal cancer cases will be diagnosed in the United States 
(Esophageal Cancer, 2006). Esophageal tumors usually lead to dysphagia (difficulty 
swallowing), pain and other symptoms, and are diagnosed with biopsy. Small and localized 
tumors are treated surgically with curative intent. Larger tumors tend not to be operable and 
hence are treated with palliative care; their growth can still be delayed with chemotherapy, 
radiotherapy or a combination of the two. In some cases chemo- and radiotherapy can render 
these larger tumors operable (Enzinger and Mayer 2003). Prognosis depends on the extent of 
the disease and other medical problems, but is fairly poor, because most patients present with 
advanced disease. By the time the first symptoms such as dysphagia start manifesting 
themselves, the cancer has already well progressed. The overall five-year survival rate 
      
 
 
(5YSR) is approximately 15%, with most patients dying within the first year of diagnosis 
(Polednak, 2003).Individualized prognosis depends largely on stage. Those with cancer 
restricted entirely to the esophageal mucosa have about an 80% 5YSR, but sub mucosal 
involvement brings this down to less than 50%. Extension into the muscularis propria 
(muscular layer of the esophagus) has meant a 20% 5YSR and extension to the structures 
adjacent to the esophagus results in a 7% 5YSR. Patients with distant metastases (who are not 
candidates for curative surgery) have a less than 3% 5YSR. 
The epidemiology of esophageal cancer is characterised by remarkable differentiation 
in incidence against geographical distribution and ethnic backgrounds. It is known that Asian 
countries, especially China and Iran have the highest rates of esophageal cancer in the world. 
A high risk region represented by the “Asian esophageal cancer belt” ranges from northern 
Iran all the way to north central China passing through Turkmenistan, Uzbekistan and 
Kazakhstan. Kashmir valley is also considered a part of this belt and the annual incidence of 
esophageal cancer in Kashmir is reported as 42 and 27 for men and women, respectively per 
100,000 individuals (Khuroo et al., 1992). Esophageal cancer has a multifactorial 
epidemiology and a synergistic effect of dietary, environmental, genetic, epigenetic and 
microbial factors is being associated with its development (Zhou et al., 1999; Langergren et 
al., 2000; Nayar et al., 2000; Shi et al., 2000; Zhang et al., 2000; Dhillon et al., 2001). The 
contributing factors are not the same in different populations of the world and a common risk 
factor is yet to be identified. The suspected risk factors for EC in Kashmir are broadly 
classified into environmental factors (including diet) and genetic factors. 
Environmental factors known to play important roles in the etiology of human cancers 
include chemical carcinogens (e.g., cigarette smoke), dietary contaminants (aflatoxin 
B1/AFB1) and physical carcinogens (ionizing and UV radiation). Lifestyles such as smoking, 
alcohol consumption, excess exposure to sunlight, fat consumption and stress may also 
contribute to cancer development (Peto, 2001; Mathers, 2004).There is ample evidence of an 
association between DNA methylation and environmental influences like exposure to viruses 
(e.g., liver (Shen, 2002), and stomach (Kang, 2002) and diet (e.g., folate) (Waterland and 
Jirtle 2003) in both normal (aged) tissues and cancer. 
Many studies have associated the unique dietary habits with the development of 
esophageal cancer in Kashmir (Khuroo et al., 1992) although; there is no strong scientific 
support for the same. Nevertheless, the findings of various studies of the presence of the 
      
 
 
considerable amounts of N-nitroso compounds like N-nitroso pipecolic acid; mono-nitroso 
piperazine; methyl benzyl nitrosoamine; diethyl nitrosoamine and dimethyl nitrosoamine in 
the local food items have further strengthened the association of such food items in the 
development of the esophageal cancer in Kashmir (Siddiqi et al., 1992a, 1992b, 1998). The 
micronutrient deficiencies or excess (vitamins A/C/E, carotenoids, zinc, and copper) may also 
have a role  in esophageal carcinogenesis (Fong et al., 1999; Lutz, 1999; Siassi et al., 2000; 
Nazir et al., 2008). 
2.3 Literature about Epigenetics 
The four nucleotide bases of DNA—Cytosine (C), Adenine (A), Guanine (G), and 
Thymine (T)—form a total of 16 possible dinucleotide pairs. One of these dinucleotides, in 
which a Cytosine is adjacent to a Guanosine in the 5' direction (the CpG dinucleotide), occurs 
at a lower than expected frequency throughout most of the human genome but at a higher 
than expected frequency in small portions of DNA that are referred to as CpG islands. These 
CpG islands are often concentrated near gene transcription start sites, the promoter regions 
where the transcription of DNA to RNA begins. In the normal cell, most of the CpG 
dinucleotides at gene promoter regions are unmethylated, whereas CpG islands found at other 
portions of the genome are generally methylated. The absence of CpG island methylation is a 
hallmark of an active transcription site that is capable of transcribing DNA to RNA. In cancer 
cells, this pattern of CpG methylation becomes disrupted: CpG islands in promoter regions of 
selected genes have an unusually high likelihood of methylation, but CpG dinucleotides that 
fall outside of promoter regions are less likely than normal to be methylated (Herman and 
Baylin 2003).The methylation of CpG islands, in association with chromatin modifications 
that accompany the change, prevents the transcription of the gene’s DNA, resulting in 
transcriptional silencing of the gene. Transcriptional silencing of genes that normally possess 
antitumor activity results in abnormal cellular events, which contribute to tumor progression. 
Thus, epigenetic gene silencing is a second mechanism, in addition to gene mutation, by 
which the production of tumor suppressing genes is disrupted (Jones and Baylin 2002).CpG 
islands, frequently located at the 5'-end regulatory regions of genes, are subject to epigenetic 
modifications including DNA methylation and histone modification that are known to play an 
important role in regulating gene expression (Jones and Baylin 2002).In normal cells, the 
majority of promoter CpG islands are protected from this epigenetic event and thus they are 
unmethylated. Conversely, in cancer cells, several promoter CpG islands are hypermethylated 
      
 
 
and form a closed repressive chromatin configuration that affects the transcription initiation 
of the corresponding genes (Esteller et al., 2001, 2002; Baylin and Ohm 2006).The term 
epigenetic refers to information which is transmitted from the parental genome to the next 
generation of cells which is not encoded by the primary DNA sequence. Epigenetic 
mechanisms are essential for the regulation of gene expression and genome integrity in 
normal cells (Bird, 2002; Li, 2002; Jaenisch and Bird 2003).Epigenetic information is often 
transmitted by methylation of the 5 carbon position of cytosine within a CpG dinucleotide, 
also referred to as DNA methylation. CpG dinucleotides are under-represented in the 
genome, but over-represented in short regions of 500– 4,000 bp (base pair) in length, known 
as CpG islands, which are rich in CpG content (Bird, 2002; Takai and Jones 2002).CpG 
islands are present in the proximal promoter regions of about 60% of the genes in the 
mammalian genome and are, generally, unmethylated in normal cells. Patterns of DNA 
methylation and chromatin structure are profoundly altered in neoplasia and include genome 
wide losses of and regional gains in DNA methylation (Feinberg and Vogelstein 
1983).Global hypomethylation was shown to cause genomic instability which in turn may 
promote secondary genetic alterations (Eden et al., 2003; Gaudet et al., 2003), whereas local 
hypermethylation of promoter regions is associated with transcriptional silencing and can 
lead to the loss of tumor-suppressor gene function. The molecular mechanisms of epigenetic 
silencing during tumor formation are only partially understood. In normal cells the pattern of 
CpG methylation is brought about by a group of enzymes known as the DNA 
methyltransferases (DNMT). The DNMTs known to date are DNMT1, DNMT1b, DNMT1o, 
DNMT1p, DNMT2, DNMT3A, and DNMT3b with its isoforms and DNMT3L (Robertson, 
2002). Methylation can be de novo (when CpG dinucleotides on both DNA strands are 
unmethylated) or maintenance (when CpG dinucleotides on one strand are methylated). 
DNMT1 has de novo as well as maintenance methyltransferase activity, and DNMT3A and 
DNMT3b are powerful de novo methyltransferases (Marzo et al., 1999; Robertson et al., 
2000; Costello and Plass 2001)(Figure 5).Methylation of various biological molecules 
including DNA is dependent on S-adenosylmethionine (SAM), the principal biological 
methyl group donor (Stern et al.,  2000; Yi  et al.,  2000). Considering the critical role of 
methylation in various cellular processes, it is understandable that any alteration in the 
availability of SAM may have a profound effect on cellular growth, differentiation and 
function in both health and illness. Methylenetetrahydrofolate reductase (MTHFR), a rate-
limiting enzyme in the conversion of homocysteine to methionine, which is the substrate for 
      
 
 
Figure 5: Cytosine gets converted into 5'methyl cytosine by the action of 
S-adenosylmethionine (SAM) which donates methyl groups 
and is converted to S-adenosyl homocysteine (SAH) in 
presence of DNMTs 
 
(Source: Review article on role of methylation) 
SAM, may play a regulatory role in the folate metabolism and methylation process 
(Bolander, 2002). Elevated homocysteine levels, either due to MTHFR mutation or a diet 
deficient in cofactors for the methylation cycle, result in the formation of S-adenosyl L-
homocysteine, which is a competitive inhibitor of SAM. This, as a result, affects methylation 
in various biological processes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
 
Epigenetic modifications include DNA methylation and covalent modification of 
histones. These alterations are reversible but very stable and exert a significant impact on the 
regulation of gene expression and the development of vertebrates (Santos and Dean 2004). In 
mammals, m
5
C is primarily located in CpG islands of promoter and first exon sequences, 
which exhibit highly conservative DNA methylation pattern. CpG islands are 0.5 to several 
kb DNA sequences that contain 60-70% of CpG dinucleotides (Baylin and Herman 2000; 
Robertson and Jones 2000; Momparler, 2003; Cottrell, 2004). Human genome contains 
29000 CpG islands (Clark and Melki 2002) and approximately half of genes possess these 
islands (Attwood et al., 2002; Das and Singal 2004). Completely methylated CpG islands are 
found only in promoters of un-transcribed autosomal genes and transcriptionally silenced 
genes of inactive female X-chromosomes (Baylin and Herman 2000). The N-terminal tails of 
histones are epigenetically modified by histone acetyltransferases (HATs), histone 
deacetylases (HDACs) and histone methyltransferases (HMTs). These enzymes acetylate, 
deacetylate or methylate  and guanidine amine groups of histone Lys (K) or Arg (R) amino 
acid residues, respectively. The multiple covalent modifications on the same histone tail 
create specific epigenetic patterns that switch genes between their active and transcriptionally 
inactive stages and correlate with distinct biological events (Zhang and Reinberg 2001; 
Moggs et al., 2004). HDACs, HATs, HMTs and DNMTs play crucial roles in the epigenetic 
regulation of gene expression involved in carcinogenesis (Sun et al., 1997; Geiman et al., 
2004). Alteration of transcriptionally active euchromatin to transcriptionally inactive 
heterochromatin requires histone remodelling enzymes HDACs, HATs, HMTs (Suv39h1/2, 
G9a, EZH2) and ATP-dependent chromatin remodeling enzymes (e.g. hSNF2H). 
Methylation level of K4, K9 and K27 amino acid residues of H3 histone corresponds to 
euchromatin, facultative heterochromatin and constitutive heterochromatin structures, 
respectively (Geiman et al., 2004). HMT (Suv39h1) attaches methyl group to K9 amino acid 
residues of H3 histone that further recruits heterochromatin protein 1 (HP1). Interactions of 
HP1 with methylated K9 of H3 histone and transcriptional complex components are essential 
for formation and maintenance of heterochromatin structure (Bannister et al., 2001; Smothers 
and Henikoff 2001; Peters et al., 2002; Cammas et al., 2004; Verschure et al., 2005).CpG 
islands, frequently located at the 5'-end regulatory regions of genes, are subject to epigenetic 
modifications including DNA methylation and histone modification that are known to play an 
important role in regulating gene expression (Jones and Baylin 2002). In normal cells, the 
majority of promoter CpG islands are protected from this epigenetic event and thus they are 
      
 
 
unmethylated. Conversely, in cancer cells, several promoter CpG islands are hypermethylated 
and form a closed repressive chromatin configuration that affects the transcription initiation 
of the corresponding genes (Esteller et al., 2001, 2002; Baylin and Ohm 2006). 
DNA hypermethylation inhibits gene transcription: Two mechanisms have been 
proposed to account for transcriptional repression via DNA methylation. In the first 
mechanism, DNA methylation directly inhibits the binding of transcription factors (TFs) such 
as AP-2, c-Myc/Myn, E2F and NFkB to their binding sites within promoter sequence. In this 
mechanism, CpG dinucleotides have to be present within the binding site of TFs, which are 
sensitive to methylation of CpG dinucleotides (Tate and Bird 1993; Singal and Ginder 
1999)(Figure 6b).The second mode of repression includes a binding of proteins specific for 
m5CpG dinucleotides to methylated DNA. Methylated DNA recruits m5CpG-binding 
(MeCP) and m5CpG-binding domain (MBD) proteins. MeCP1 and MeCP2 bind specifically 
to methylated DNA in whole genome and form spatial obstacle that unable binding of TFs to 
promoter sequences (Figure 2). MeCP1 represses transcription of specific genes, which are 
controlled by densely methylated promoters containing more than ten m5CpG dinucleotides. 
MeCP2 can bind to a single symmetrically located m5CpG pair in two DNA strands 
(Hendrich and Bird 1998) (Figure 6c). MBD protein family includes MBD1, MBD2, MBD3 
MBD4, and uncharacterized Kaiso complex, which binds to methylated DNA. MBD1 binds 
to symmetrically methylated CpG dinucleotides and inhibits gene expression by blocking TFs 
interaction with the promoter (Fujita et al., 2000). MBD2 may bind to methylated DNA and 
actively demethylates DNA in vivo and in vitro (Ng HH et al., 1999; Szyf et al., 2004). 
MBD3 is targeted to methylated DNA through association with the MBD2 and is a 
component of the chromatin remodeling protein complex (Ballestar et al., 2003). MBD4 is 
thymine and uracil glycosylase involved in DNA mismatch repair, formed during C and m5C 
deamination, respectively (Hendrich et al., 1999; Fujita et al., 2003). MBD1, MBD2, 
MeCP2, and Kaiso complex are able to interact with HDAC1 and HDAC2, which deacetylate 
histones and remodel chromatin structure (Baylin and Herman 2000; Robertson and Jones 
2000; Brown and Strathdee 2002; Das and Singal 2004; Laird, 2005). 
 
 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Repression of transcription via CpG dinucleotide methylation. 
Promoter sequence binds transcription factors (TFs) and RNA 
polymerase II (POL II) that initiates transcription (A). 
Methylation of CpG within promoter binding site directly inhibits 
requirement of TFs and represses transcription (B). Methylated 
DNA binds m5CpG binding (MeCPs) and m5CpG-binding 
domain (MBDs) proteins forming spatial obstacle that prevents 
binding of TFs to promoter sequence 
 
(Source: Review article on role of methylation) 
      
 
 
DNA methylation in cancer has become the topic of intense investigation. As 
compared with normal cells, the malignant cells show major disruptions in their DNA 
methylation patterns (Baylin and Herman 2000).Hypermethylation involves CpG islands 
whereas Hypomethylation usually involves repeated DNA sequences, such as long 
interspersed nuclear elements (Ehrlich, 2002).Reports of hypermethylation in cancer far 
outnumber the reports of hypomethylation in cancer. There are several protective 
mechanisms that prevent the hypermethylation of the CpG islands. These include active 
transcription, active demethylation, replication timing, and local chromatin structure 
preventing access to the DNA methyltransferase (Clark and Melki 2002).To date, nearly 50% 
of numerous genes have been found to undergo hypermethylation in cancer. The genes that 
are susceptible are the genes involved in cell cycle regulation (p16
INK4a
, p15
INK4a
, Rb, p
14ARF
) 
genes associated with DNA repair (hMLH1, BRCA1, MGMT), apoptosis (DAPK, TMS1), 
angiogenesis (THBS1, VHL), invasion (CDH1, TIMP3), drug resistance, detoxification, 
differentiation, and metastasis (Jones and Baylin 2002). 
Hypomethylation is the second kind of methylation defect that is observed in a wide 
variety of malignancies (Feinberg and Vogelstein 1983; Kim et al., 1994). It is common in 
solid tumors such as metastatic hepatocellular cancer (Lin et al., 2001), in cervical cancer 
(Lin et al., 2001), prostate tumors (Bedford and Helden 1987), and also in hematologic 
malignancies such as B-cell chronic lymphocytic leukemia (Ehrlich 2002). The global 
hypomethylation seen in a number of cancers, such as breast, cervical, and brain, show a 
progressive increase with the grade of malignancy (Ehrlich 2002). The pericentric 
heterochromatin regions on chromosomes 1 and 16 are heavily hypomethylated in patients 
with immunodeficiency, centromeric instability, and facial abnormalities and in many 
cancers. A mutation of DNMT3b has been found in patients with immunodeficiency, 
centromeric instability, and facial abnormalities, which causes the instability of the chromatin 
(Hansen et al., 1999; Okano et al., 1999). Hypomethylation has been hypothesized to 
contribute to oncogenesis by activation of oncogenes such as cMYC and H-RAS (Feinberg 
and Vogelstein 1983) or by activation of latent retro transposons (Singer et al., 1993; Alves et 
al., 1996) or by chromosome instability (Tuck-Muller et al., 2000). Long interspersed nuclear 
elements are the most plentiful mobile DNAs or retro transposons in the human genome. 
Hypomethylation of these mobile DNAs causes transcriptional activation and has been found 
in many types of cancer, such as urinary bladder cancer (Jurgens et al., 1996). 
      
 
 
2.4 Literature about hMLH1 Gene 
The official name of this gene is “mutL homolog 1, colon cancer, nonpolyposis type 2 
(E. coli).” hMLH1 is the gene's official symbol. The hMLH1 gene is also known by other 
names, as COCA2, DNA mismatch repair protein hMLH1, FCC2, HNPCC, mutL (E. coli) 
homolog 1 (colon cancer, nonpolyposis type 2) and MutL protein homolog 1. The hMLH1 
gene is located on the short (p) arm of chromosome 3 at position 21.3 from base pair 
37,034,840 to base pair 37,092,336 (Figure 7). About 50 percent of all cases of Lynch 
syndrome with an identified gene mutation are associated with mutations in the hMLH1 gene. 
Several hundred hMLH1 mutations that predispose people to colorectal cancer and other 
cancers have been found. These mutations prevent the production of hMLH1 protein or lead 
to an altered version of this protein that does not function properly. When the hMLH1 protein 
is absent or ineffective, the number of mistakes that are left unrepaired during cell division 
increases substantially. If the cells continue to divide, errors accumulate in DNA; the cells 
become unable to function properly and may form a tumor in the colon or another part of the 
body. The DNA mismatch repair (MMR) protein hMLH1 is encoded by the MutL homolog 1 
(hMLH1) gene in humans and is a homologue of the DNA MMR gene mutL of Escherichia 
coli. The MMR function is associated with DNA replication, to correct for deficiencies in 
DNA polymerase proofreading function. A missing gene or mutations of this gene and other 
MMR genes (MSH2, MSH6, or PMS2) leads to microsatellite instability (MSI) and this 
dysfunction is highly associated with hereditary non-polyposis colon cancer (HNPCC or 
Lynch syndrome) (Bronner et al., 1994). The hMLH1 gene provides instructions for making a 
protein that plays an essential role in DNA repair. This protein fixes mistakes that are made 
when DNA is copied (DNA replication) in preparation for cell division. The hMLH1 protein 
joins with another protein, the PMS2 protein, to form an active protein complex. This protein 
complex coordinates the activities of other proteins that repair mistakes made during DNA 
replication. The repairs are made by removing a section of DNA that contains mistakes and 
replacing the section with a corrected DNA sequence (Jascur and Boland 2006). Human 
MutL homologue or hMLH1 is a member of the mismatch repair system whose function is to 
replicate the genome faithfully (Ahuja et al., 1998). Deficiencies in this system result in 
mutation rates 100-fold higher than those observed in normal cells (Thomas et al., 1996; 
Jiricny, 2006). 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: hMLH1 gene on short arm of chromosome 3 at position 21.3 
 
(Source: Handbook Genetics home reference) 
      
 
 
A variety of genetic lesions has been demonstrated to be involved in esophageal 
cancer, including p53-Rb pathway with gene amplifications, loss of heterozygosity or 
homozygous deletions, point mutations, and chromosomal rearrangements (Chen and Yang 
2001; Wang et al., 2002; Enzinger and Mayer 2003). DNA methylation of the promoter 
region of certain cancer-associated genes is one potential early detection biomarker 
(Kawakami et al., 2000; Hibi et al., 2001; Yao et al., 2005). Previous studies have shown that 
smoking and alcohol consumption increase the risk of developing microsatellite-unstable 
tumors (Slattery et al., 2000; Slattery et al., 2001). The exact mechanism of DNA 
hypermethylation by alcohol is unknown. However, it has been hypothesized that alcohol 
could influence carcinogenesis by influencing mucosal cell proliferation and related 
histological changes (Kune and Vitetta 1992). These changes have been associated with 
mucosal hyper regeneration, which may make the mucosa more susceptible to the action of 
other carcinogens such as cigarette smoke (Kune and Vitetta 1992). Therefore, alcohol 
consumption might increase the bioavailability of DNA-binding smoke components in the 
mucosa of the upper digestive tract, increasing the plasma levels of these compounds, or 
might modify the metabolism of pro-carcinogenic compounds by inducing specific metabolic 
pathways involving an aberrant mismatch repair system (Izzotti et al., 1998). The DNA 
MMR protein hMLH1 is encoded by the MutL homolog 1 (hMLH1) gene in humans and is a 
homologue of the DNA MMR gene mutL of Escherichia coli. The MMR function is 
associated with DNA replication, to correct for deficiencies in DNA polymerase proofreading 
function. A missing gene or mutations of this gene and other MMR genes (MSH2, MSH6, or 
PMS2) leads to microsatellite instability (MSI) and this dysfunction is highly associated with 
hereditary non-polyposis colon cancer (HNPCC or Lynch syndrome) (Bronner et al., 
1994).Loss of function of the DNA mismatch repair gene hMLH1 by hypermethylation of its 
promoter has been described in different cancer types, such as colorectal and endometrial 
cancers (Herman et al., 1999; Esteller et al., 2001). Methylation of the hMLH1 gene in 
3p21.3 and its correlation with a mismatch repair defect and high microsatellite instability 
(MSIH) is well characterised in sporadic colorectal cancer, where this phenotype is 
associated with better patient survival (Sinicrope et al., 2006). 
It has been shown that methylation in the promoter region of hMLH1 correlates with 
decreased activity of the gene (Kane et al., 1997). Next to the main cancer type where this 
gene is inactivated, HNPCC, this gene is epigenetically inactivated also in other types of 
cancer, for example, in sporadic endometrial carcinoma (Esteller et al., 1998), gastric cancers 
      
 
 
(Fleisher et al., 1999), sporadic CRC (Kane et al., 1997; Herman et al., 1998), ovarian tumors 
(Gras et al., 2001a), NSCLC (Wang et al., 2003), oral squamous cell carcinoma (SCC) 
(Czerninski  et al., 2009), neck SCC (Liu et al., 2002; Steinmann et al., 2009), and acute 
myeloid leukemia (AML) (Seedhouse et al., 2003). Constitutional methylation of the hMLH1 
gene, characterized by soma-wide methylation of a single allele and transcriptional silencing, 
has been identified in a subset of Lynch syndrome cases lacking a sequence mutation in 
hMLH1 (Gazzoli et al., 2002; Suter et al., 2004; Hitchins et al., 2007). This particular 
example provides strong support for the proposal that methylation of a DNA repair gene can 
be a crucial mechanism in carcinogenesis.In tumor types that rarely show the classic MMR-
deficient phenotype and that are rare in HNPCC kindreds, such as breast and lung carcinomas 
or gliomas, hMLH1 is not hypermethylated (Esteller et al., 1998). However, hMLH1 
promoter hypermethylation occurs in the majority of sporadic colorectal, endometrial, and 
gastric carcinomas showing MSI (Ottini et al., 1997; Yamamoto et al., 1997). 
Cancer and some chronic inflammatory conditions have been associated with genomic 
instability (Ishitsuka et al., 2001; Gao et al., 2005). The MMR system maintains genomic 
integrity, and it is accepted that defects in MMR genes are responsible for the microsatellite 
instability (MSI) observed in different diseases (Brentnall et al., 1995; Lynch and Hoops 
2002). Approximately 27% of esophageal tumors deficient in hMLH1 repair gene expression 
have been associated with MSI (Hayashi et al., 2003). It was also observed hMLH1 
hypermethylation to be associated with MSI in about 42% of esophageal cancers (Vasavi and 
Hasan). 
MMR gene silencing has been reported in several cancers and inflammatory 
conditions such as inflammatory bowel disease, head and neck cancers, and cancers of the GI 
tract (Bubb et al., 1996; Wang et al., 2001; Kang et al., 2002). In most of these studies, 
immunohistochemistry and mRNA expression analysis showed the absence of hMLH1 
protein; however, no mutations were found to be responsible for this (Liu et al., 1995; Kane 
et al., 1997). Epigenetic silencing through promoter methylation of the hMLH1 repair gene 
was associated with loss of hMLH1 protein expression (Razin et al., 1980; Kane et al., 1997). 
In esophageal cancers, there are controversial reports regarding the association of 
hypermethylation with hMLH1 gene silencing (Nie et al., 2002; Hayashi et al., 2003). 
In this study it was attempted to identify in individuals with esophageal cancer 
whether the altered methylation status of promoter region of Mismatch Repair (hMLH1) gene 
      
 
 
could be used as a molecular marker associated with esophageal carcinogenesis. For the first 
time such a study was conducted regarding this Mismatch Repair (hMLH1) gene as related to 
esophageal cancer in the population of Kashmiri origin. To determine the status of Mismatch 
Repair (hMLH1) gene promoter methylation in Esophageal Cancer Cases from the population 
of Kashmiri origin, we performed Methylation Specific Polymerase chain reaction for 
hMLH1 gene in 50 surgically resected esophageal cases and compared with that of 20 
histopathologically confirmed normal tissues. For that First of all Genomic DNA was 
Isolated from esophageal samples and then the DNA sample was treated with sodium 
bisulfite solution which converts by deamination unmethylated cytosine’s present in DNA 
into uracil and does not affect methylated cytosines, due to this  methylated and unmethylated 
cytosines can be distinguished. The mechanism behind the bisulfite treatment is shown in 
Figure 8. Then methylation specific polymerase chain reaction (MS-PCR) was performed. 
The principle of the method lies in the amplification of the target DNA (already bisulfite 
treated) by different primer sequence; 
 one for methylated version of the gene  
 one for the unmethylated version of the gene 
Thus by visualising the MS-PCR product we can easily determine whether 
amplification is by methylated or unmethylated primers. 
 
 
 
 
      
 
 
 
 
 
 
 
 
  
Figure 8: Conversion of cytosine to uracil by bisulfite treatment 
 
(Source: Bisulfite sequencing Wikipedia) 
      
 
 
MATERIALS AND METHOD: 
3.1 Case Control Study 
The Study was a Case Control undertaken to understand the etiology of esophageal 
cancer in the population of Kashmiri origin. This case control study was designed to assess 
the relationship of promoter hypermethylation of Mismatch Repair Gene (hMLH1) with 
esophageal cancer. Also further an association of hypermethylation of gene with esophageal 
cancer in relation to clinicopathological features of Gender and Age was evaluated and thus 
further two sub-groups of Gender as Male and Female and Five more sub-groups of age as 
upto-39 years, 40-49 years, 50-59 years, 60-69 years, and above-70 years were designed and 
are listed in Table 2 in results. The Esophageal cancer samples were collected from 
Endoscopic section of Shri Maharaja Hari Singh (S.M.H.S) Hospital including resected 
esophageal samples from Department of Surgery, S.M.H.S Hospital Srinagar. The controls 
were taken from the adjacent tissue of the Esophageal cancer.A total of 70 esophageal tissue 
specimens comprising 50 histopathologically confirmed tumor tissues and 20 
histopathologically confirmed normal corresponding tissues as controls were collected for 
analysis in this study. No patient received pre-operative radiation or chemotherapy (Coia et 
al., 1995).Record was maintained of the complete case history of the patients. 
The various methods that were used to analyse the epigenetic silencing of DNA 
mismatch repair gene by its promoter hypermethylation at CpG islands as a part of this study 
are described under: 
3.2 Cases (Patients and Specimens) 
All the esophageal cancer patients that were referred to endoscopy section 
Government Shri Maharaja Hari singh (S.M.H.S) Hospital and operated in the Department of 
Surgery, Government S.M.H.S Hospital, Srinagar during the study period were included in 
the study irrespective of their age, gender and stage of the cancer. 
3.2a. Inclusion Criteria 
The diagnosis of esophageal cancer was based on the standard histopathological 
criteria. The criteria for including a subject as case in the study were: 
 All histopathologically confirmed patients irrespective of Cancer stage, age, and 
gender. 
      
 
 
 Native patients belonging to Kashmir valley. 
3.2b. Exclusion Criteria 
Under the following conditions the patients were not recruited in the study: 
 Patients who had received prior chemo or radiotherapy. 
 Patients not belonging to Kashmir valley. 
 Patients who suffered from any other kind of malignancy 
3.3 Controls (Adjacent Normals) 
Esophageal biopsies from Endoscopic section of S.M.H.S Hospital including resected 
esophageal samples from Department of Surgery, S.M.H.S Hospital which were 
histopathologically confirmed as normal were taken as controls. 
3.3a. Inclusion criteria 
 All histopathologically confirmed Normal Esophageal tissues. 
 Native population of the Kashmiri origin. 
3.3b. Exclusion criteria 
 Patients who suffered from any other kind of malignancy. 
 Patients not of Kashmiri origin. 
3.4 Collection of Esophageal Tissue Samples 
The Esophageal cancer and adjacent control sample were collected from the 
Endoscopic Section and Department of Surgery of  Government S.M.H.S Hospital and were 
put in sterilized labelled plastic vials (50 ml volume ) containing 10 ml of normal saline and 
transported from the theatres to the laboratory on ice and  stored at -80
 o
 C for further 
analysis. 
Esophageal Tissue samples were divided into two parts: 
 One part was sent to histopathological diagnosis. 
 Other half was stored at -800C for molecular investigations. 
      
 
 
Only histopathologically confirmed cases and controls were included for molecular 
analysis. Written informed consent was obtained from all the subjects included in the study 
and was carried out in accordance with the principles of the Helsinki Declaration. Complete 
Clinicopathological record was maintained for both cases and controls. 
3.5 Genetic Analysis of Histopathologically Confirmed Cases and Controls 
3.5a. Extraction of Genomic DNA 
High Molecular Genomic DNA from the histopathologically confirmed fresh 
Esophageal Cases and adjacent control tissue samples was extracted by kit based method. 
The kit used was Quick- g DNA
TM
 MiniPrep supplied by ZYMO RESEARCH. The protocol 
followed was as directed by the company as: 
 Briefly, 25 to 50 mg of tissue was taken and the cells were mechanically homogenised 
in 500 µl Genomic Lysis Buffer (provided in the kit). 
 The lysate was centrifuged at 10,000 X g for 5 min. and the supernatant transferred to 
Zymo-Spin
TM
 Column in a Collection Tube and again centrifuged at 10,000 X g for 1 
min. 
 Flow through along with the Collection tube was discarded and the Zymo-SpinTM 
Column transferred to a new Collection tube and 200 µl of DNA Pre-Wash Buffer 
(provided in the kit) was added to the tube and centrifuged at 10,000 X g for 1 min., 
followed by the addition of 500 µl of g- DNA Wash Buffer to the Zymo-Spin
TM
 
Column and again centrifuged at 10,000 X g for 1 min. 
 The spin column was transferred to a clean micro centrifuge tube and DNA was 
eluted from it into the micro centrifuge tube by addition of 50 µl of DNA Elution 
Buffer (provided in the kit). 
The DNA eluted was stored at 4
0
C for a short time but the vials were kept at -20
o
C for 
longer duration storage for further investigation. 
3.5b. Qualitative Analysis of Genomic DNA 
The integrity of the genomic DNA was examined by gel electrophoresis using 1 % 
agarose gel to which 10 µl/ 50ml (of gel solution) of fluorescent dye ethidium bromide was 
added during its cooling and then gel was cast and 20 µl wells were cast into it by usage of 
suitable combs. 2µl of each DNA sample was mixed with 1µl of 1X DNA loading dye and 
      
 
 
was loaded in the gel. Electric current was applied at 50 volt until DNA entered in to the gel 
and was raised to 70 volt for rest of the run. Run was stopped when the dye had travelled 
nearly 2/3rd of the gel. DNA in the gel was visualized with the help of Gel doc system 
(AlphaimagerTM 2200, Alpha Innotech Corporation) under UV light and picture was 
captured by using CCD camera system and is shown in Figure 9. 
1X loading dye consists of: 
 4.16 mg bromophenol blue 
 4.16 mg xylene cyanol 
 0.66g sucrose 
 Final volume 1ml with deionized water 
3.5c. Quantitative Analysis of Genomic DNA 
The quantity of the above isolated Esophageal cancer and histopathologically 
confirmed normal genomic DNAs was determined by measuring optical density (OD) at 
260nm and 280nm by double beam spectrophotometer (Spectron 2206) and the concentration 
was determined by using the fact that absorbance 1 absorbance unit equates to 50 µg/ cm
3
 
and therefore, the concentration of DNA sample is given by the following equation: 
DNA (µg/ml) = A260 x 50 x dilution factor 
The ratio of 260/280nm was calculated and the DNA samples for which the ratio was 
1.7-1.9 was considered for the future use. The DNA was stored at 4
o
C for a short time but the 
vials were kept at -20
o
C for longer duration storage. 
3.5d. Bisulfite Treatment to Genomic DNA 
DNA methylation patterns in the CpG islands of promoter region of gene was 
determined by chemical treatment with sodium bisulfite and subsequent MSP as described by 
(Herman et al., 1996).The above extracted Genomic DNA was treated with sodium bisulphite 
solution under carefully controlled conditions by which unmethylated cytosine’s are 
converted by deamination into uracil, but methylated cytosines are resistant to the reagent. 
This was done by an EZ DNA Methylation –Direct TM Kit supplied by ZYMO RESEARCH. 
The protocol is as under: 
 500-1000 ng of above isolated DNA samples were taken in different eppendorf tubes. 
      
 
 
 And to each tube 5 µl of M-Dilution Buffer was added and final volume was made to 
50 µl with distilled water. 
 Then 100 µl CT-Conversion Reagent was added to each tube (preparation of CT-
Conversion reagent is given below) and all tubes were placed in dark at 50
0
-55
0
c for 
12-16 hrs. 
 After that all samples were placed on ice for 5-10 mins. 
 400 µl of M-binding buffer was added into the Zymo-SpinTM IC Column and column 
was placed into a provided Collection Tube. 
 Sample was loaded (from step 4) into the Zymo-SpinTM IC Column containing M-
binding buffer. Cap was closed and column was mixed by inverting several times. 
 Centrifugation was done at full speed (≥10,000× g) for 30 seconds. Flow-through was 
discarded. 
 Now 100 µl of M-Wash Buffer was added to the column and Centrifugation was done 
at full speed for 30 seconds. 
 200 µl of M-Desulphonation Buffer was added to the column and was incubated at 
room temperature (20
0
C-30
0
C) for 15-20 minutes. After the incubation, centrifugation 
was done at full speed for 30 seconds. 
 Again 200 µl of M-Wash Buffer was added to the column and was centrifuged at full 
speed for 30 seconds; another 200 µl of M-Wash Buffer was added and again 
centrifuged for an additional 30 seconds. 
 Column was placed into a 1.5 ml micro centrifuge tube and 15 µl of M-Elution Buffer 
was added directly to the column matrix. Centrifugation for 30 seconds at full speed 
was done to elute the DNA. 
The DNA was ready for immediate analysis or can be stored at or below -20
0
C for 
later use. 
Preparation of CT-Conversion Reagent 
The CT-Conversion Reagent supplied within this kit was a solid mixture and must be 
prepared prior to first use. Prepare as follows: 
 790 µl of M-Solubilisation Buffer and 300 µl of M-Dilution Buffer were added to the 
tube of CT Conversion Reagent. 
      
 
 
 Mixing was done at room temperature with frequent vortexing or shaking for 10 
minutes. 
 160 µl of M-Reaction Buffer was added and mixed for an additional 1 minute. 
3.5e. Methylation-Specific polymerase chain reaction (MS-PCR) 
All the cytosines in the unmethylated product were converted to thymines after 
bisulfite treatment and amplification, suggesting that the hMLH1 gene is unmethylated. 
However, the cytosines in the CpG dinucleotides of methylated product remained unchanged, 
as methylated cytosines cannot be modified by bisulfite, which indicated that the CpG islands 
of the gene are methylated. This alternative method of methylation analysis also uses 
bisulfite-treated DNA but avoids the need to sequence the area of interest (Herman et al., 
1996). Instead, primer pairs were designed themselves to be "methylated-specific" by 
including sequences complementing only unconverted 5-methylcytosines, or, on the 
converse, "unmethylated-specific", complementing thymines converted from unmethylated 
cytosines. Methylation was determined by the ability of the specific primer to achieve 
amplification. This method was particularly useful to interrogate CpG islands with possibly 
high methylation density, as increased numbers of CpG pairs in the primer increase the 
specificity of the assay. Placing the CpG pair at the 3'-end of the primer also improves the 
sensitivity. The initial report using MSP described sufficient sensitivity to detect methylation 
of 0.1% of alleles. In general, MS-PCR and its related protocols were considered to be the 
most sensitive when interrogating the methylation status at a specific locus. The principle 
method lies in the amplification of the target DNA (already Bisulfite treated) by different 
primer sequence: 
 One for Methylated version of the gene 
 One for the Unmethylated version of the gene 
Thus by visualising the PCR product we have easily determined whether 
amplification was by Methylated or Unmethylated primers. This determines whether CpG’s 
were Methylated or Unmethylated. 
The primers used for amplification of promoter region of gene were listed in the 
literature along with PCR-annealing temperatures, fragment sizes, and NO. Of PCR cycles 
and are shown in the Table 1 (Steven et al., 1999, 2001; Hong et al., 2005; Edward et al., 
2006). 
      
 
 
Table 1: Primer Sequences and annealing Temperatures of hMLH1 gene 
Gene Sequence (5ʹ-3ʹ) 
Tm 
(◦C) 
Size 
(bp) 
PCR 
cycles 
(U) 
F 
5'-
TTTTGATGTAGATGTTTTATTAGGGTTG
T-3' 
60 115 30 
R 5'-ACCACCTCATCATAACTACCCACA-3' 
(M) 
F 5'-ACGTAGACGTTTTATTAGGGTCGC-3' 
58 110 30 
R 5'-CCTCATCGTAACTACCCGCG-3' 
 
 
 
For methylation-specific polymerase chain reaction (MS-PCR) the total reaction 
volume was 25 µl containing: 
 1.25 µl bisulfite modified DNA (50–100 ng) 
 5 µl of each forward and reverse primer (150 ng of each) 
 1.50 µl of dNTP's (1.25 mM/L) 
 0.2 µl Taq Polymerase (1 U/reaction) 
 2.5 µl 1X PCR buffer (Bangalore Genei, Bangalore) and Final volume was made to 
 25 µl with de-ionized water. 
The modified DNA was taken into two PCR vials in equal quantity and same amount 
of all reagents was added to both the vials except in one vial, methylated primers and in 
other, non-methylated primers were used. PCR amplification was achieved using a Thermal 
cycler (Gradient thermal cycler from EPPENDORF MASTERCYCLER PRO). 
PCR reactions were started by denaturation at 95
0
C for 5 min, followed by 30 cycles 
at 94
0
C for 30 s, 60
0
C (for unmethylated hMLH1), 58
0
C (for methylated hMLH1) for 30 s, 
and 72
0
C for 30 s, with a final extension at 72
0
C for 4 min. 
All MS-PCRs were performed with controls for unmethylated DNA (DNA from 
normal lymphocytes Negative Control) and methylated DNA [normal lymphocyte DNA 
treated in vitro with SssI methyltransferase Positive Control (ZYMO RESEARCH)]. 
 
      
 
 
3.5f. Electrophoresis of MS-PCR products 
After the MS-PCR is over the resulted amplification products was visualized under 
UV-illumination. 10 µl of each MS-PCR product was directly loaded on 3% agarose, stained 
with ethidium bromide and visualized under UV illumination. 
3.6 Data Analysis And Statistics 
The χ2-test with Odds ratio was used to examine the differences in the distribution of 
hypermethylation in promoter region of gene between cases and controls and Fishers exact 
test was used in case of studying the male and female groups as cell frequency was less than 
5 in some cells.  ORs with 95% CIs were computed using unconditional logistic regression 
using Graph Pad Prism Software Version 5.0 by Graph Pad Software 2236, Avenida de la 
Playa, La Jolla, CA 92037, USA. 
 
  
      
 
 
 
RESULTS: 
n this study it was attempted to identify in individuals with esophageal cancer whether the 
altered methylation status of promoter region of Mismatch Repair (hMLH1) gene could be 
used as a molecular marker associated with esophageal carcinogenesis. For the first time such 
a study was conducted regarding this Mismatch Repair (hMLH1) gene as related to 
esophageal cancer in the population of Kashmiri origin. 
4.1 Methylation Status of Promoter Region of Mis-Match Repair Gene (hMLH1) in 
Esophageal Cancer 
To determine the status of Mismatch Repair (hMLH1) gene promoter methylation in 
Esophageal Cancer Cases from the population of Kashmiri origin, Methylation Specific 
Polymerase chain reaction for hMLH1 gene was performed in 50 surgically resected 
histopathologically confirmed esophageal cases and compared with that of 20 
histopathologically confirmed normal tissues. The Study included 33 Male cases and 17 
Female cases out of which only 04 cases were below the age of 40 years and remaining 46 
cases were above the age of 40 years and Controls include 12 Males and 08 Females out of 
which 02 controls were below the age of 40 years and remaining 18 controls were above the 
age of 40 years which is tabulated in Table 2.The gel photo of isolated Genomic DNA 
samples is shown in Figure 9. 
Table 2: Number of Males and Females in Cases vs Controls 
GENDER CASES(50) CONTROLS(20) 
Male 33 12 
Female 17 08 
Age (years) 
Upto-39 04 02 
40-49 06 03 
50-59 13 05 
60-69 20 07 
70-above 07 03 
I 
      
 
 
 
Figure 9: Representative Gel Picture showing the integrity of the Genomic 
DNA on 1.0% agarose 
 
Lane 1 Gel Image of Genomic DNA 06, histopathologically confirmed 
Esophageal      Cancer Case 
Lane 2 No Gel Image of Genomic DNA 01, histopathologically confirmed 
Esophageal Cancer case 
Lane 3 Gel Image of Genomic DNA 17, histopathologically confirmed 
Esophageal Cancer case 
Lane 4 Gel Image of Genomic DNA 18, histopathologically confirmed 
Esophageal Cancer case 
Lane 5 Gel Image of Genomic DNA 67, histopathologically confirmed 
Esophageal Cancer case 
Lane 6 Gel Image of Genomic DNA 68, histopathologically confirmed 
Esophageal Cancer case  
Lane 7 Gel Image of Genomic DNA 24, histopathologically confirmed 
Esophageal Normal sample 
Lane 8 Gel Image of Genomic DNA 31, histopathologically confirmed 
Esophageal Normal sample 
 
 
 
 
 
 
      
 
 
4.2 Result Analysis 
Analysis of promoter methylation of hMLH1 was carried out in resected 50 invasive 
primary esophageal cancer cases, respectively. Figure 10 and 11 shows representative 
examples of MS-PCR results. The frequency of promoter hypermethylation was 56% (28 out 
of 50) for hMLH1 gene. Among the 50 cases, less than a half exhibited at least one 
methylated primer amplification (<50%). In other hand, for some cases, we observed both the 
methylated and unmethylated primer amplification, this can be probably explained by the 
presence of infiltrating lymphocytes and/or non-malignant epithelial cells in the primary 
tumors.  
4.2a. Cases vs Controls 
It was observed that 28 out of 50 (56%) of the esophageal Cancer cases showed bands 
in methylated (M) wells or in both wells which confirms that Promoter region of Mismatch 
Repair Gene (hMLH1) gene is hypermethylated (Figure 10: Case 67 and 68). However 22 out 
of 50 (44%) of the esophageal cancer cases does not showed bands in methylated wells but in 
unmethylated wells confirms Promoter region of Mismatch Repair Gene (hMLH1) is not 
hypermethylated (Figure 10: Case 05).In case of histopathologically confirmed esophageal 
controls it was seen that 17 out of 20 (85%) showed no bands in methylated (M) wells but 
bands were seen in unmethylated (U) wells which confirms hMLH1 gene promoter is not 
hypermethylated (Figure 11: Control 18,06 and 08) while in remaining 03 histopathologically 
confirmed esophageal Controls ,bands were seen in methylated (M) wells as well as in 
unmethylated wells which confirms that remaining 15% of histopathologically confirmed 
esophageal  Controls were hypermethylated (Figure 11: Control 67,Figure 12: histogram and 
Table 3). Statistically the Association of promoter Hypermethylation with esophageal cancer 
was found significant with the p value =0.0028 and was evaluated by χ2 (Chi square) test with 
Odds ratio (O.R=7.2121, 95% C.I=1.822-27.79).  
 
 
      
 
 
 
Figure 10: MS-PCR was performed with primers specific for Methylated (M) and 
Unmethylated (U) regions of Cases. Product sizes: hMLH1 Unmethylated, 115 
bp; hMLH1 Methylated, 110 bp 
 
Lane 1 Band Seen in methylated well  Means Esophageal 67 cancer case 
shows hMLH1 gene promoter 
hypermethylation 
Lane 2 Band not Seen in unmethylated 
well 
Lane 3 Band  seen in methylated well Means Esophageal 68 cancer case 
shows hMLH1 gene promoter 
hypermethylation 
Lane 4 Band also Seen in unmethylated 
well 
Lane 5 Band not seen in methylated 
well 
Means Esophageal 05 cancer case 
does not shows hMLH1 gene 
promoter  hypermethylation Lane 6 Band Seen in unmethylated well 
Lane 7 Band seen in methylated well Means positive control (universal 
methylated DNA) shows 
amplification in methylated well only 
Lane 8 Band not Seen in unmethylated 
well 
 
 
 
 
 
      
 
 
 
Figure 11: Methylation analysis of MutL homolog 1 (hMLH1) gene promoter in Normal 
Esophageal controls. MSP was performed with primers specific for Methylated 
(M) and Unmethylated (U) regions. Product sizes: hMLH1 Unmethylated, 115 
bp; hMLH1 Methylated, 110 bp 
 
Lane 1 Band Seen in methylated well  Means  Normal  Esophageal control 67  
promoter is  hypermethylated 
 
Lane 2 Band also Seen in unmethylated well 
Lane 3 Band not seen in methylated well Means  Normal  Esophageal control 18 
promoter is not hypermethylated 
 
Lane 4 Band Seen in unmethylated well 
Lane 5 Band not seen in methylated well Means  Normal  Esophageal control 06 
promoter is not hypermethylated 
 
Lane 6 Band Seen in unmethylated well 
Lane 7 Band not seen in methylated well Means  negative control(lymphocyte 
DNA) shows amplification in 
unmethylated well only 
Lane 8 Band Seen in unmethylated well 
 
 
 
 
 
 
      
 
 
Table 3: Promoter Region Hypermethylation of Mismatch Repair (hMLH1) of Case vs 
Control as; Total, Hypermethylation, Non-hypermethylation and Frequency  
PARAMETER   CASES (50) CONTROL (20) 
HYPERMETHYLATION 28 03 
NON-HYPERMETHYLATION 22 17 
FREQUENCY 56% 15% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
 
 
Figure 12: Promoter region hypermethylation of Mismatch Repair (hMLH1) 
gene of Cases vs Controls as; Total, Hypermethylation, Non-
hypermethylation and Frequency 
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4.3 FURTHER AS REGARDING THE GENDER TWO MORE SUB-GROUPS OF 
MALE AND FEMALE WERE DESIGNED AND REVEALED THE FOLLOWING 
DATA 
4.3a. Males 
Promoter region hypermethylation of hMLH1 gene was found in 20 Male Cases out 
33 (60%) and in Controls 02 out of 12 (16%).which is represented in histogram in Figure 13 
and data in Table 4, which is Statistically Significant Association with p=0.0165 and was 
evaluated by Fishers exact test with odds ratio (O.R=7.6922, 95% C.I=1.446-40.92, 
p=0.0165) 
4.3b. Females 
In case of Females Promoter region hypermethylation of hMLH1 gene was found in 
08 Cancer Cases out of 17(47%) and 01 Control out of 08 (12%),which is shown in 
histogram in Figure 14 and data Tabulated in Table 5.The association was found insignificant 
statistically because p=0.1822 (O.R=6.2222,95% C.I=0.6225-62.19 and p=0.1822) 
4.3c. Total 
From the data and results it was found that the frequency of methylation status of 
MutL homolog 1 (hMLH1) gene in Esophageal Cancer Cases was high in Males 20 out of 33 
(60%) compared to Females 08 out of 17 (47%) which shows an insignificant association 
statistically as p=0.3822,odds ratio=1.7310 and 95% C.I=0.5312-5.639. This is represented 
histogramically in Figure 15 and data Tabulated in Table 6. 
 
 
 
 
 
 
      
 
 
Table 4: Promoter Region Hypermethylation of Mismatch Repair gene (hMLH1) in 
Males of Case vs Control as; Total, Hypermethylation, Non-hypermethylation and 
Frequency 
PARAMETER CASE MALES (33) CONTROL MALES (12) 
HYPERMETHYLATION 20 02 
NON-HYPERMETHYLATION 13 10 
FREQUENCY 60% 16% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
 
 
Figure 13: Promoter Region Hypermethylation of Mismatch Repair (hMLH1) gene of 
Males in Cases vs Controls as; Total, Hypermethylation, Non-
hypermethylation and Frequency 
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Table 5: Promoter Region Hypermethylation of Mismatch Repair gene (hMLH1) in 
Females of Case vs Control as; Total, Hypermethylation, Non-hypermethylation and 
Frequency 
PARAMETER CASE FEMALES (17) CONTROL FEMALES (08) 
HYPERMETHYLATION 08 01 
NON-HYPERMETHYLATION 09 07 
FREQUENCY 47% 12% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
 
 
Figure 14: Promoter Region Hypermethylation of Mismatch Repair (hMLH1) gene of 
Females in Cases vs Controls as; Total, Hypermethylation, Non-
hypermethylation and Frequency  
 
 
 
 
 
 
 
 
 
 
 
0
2
4
6
8
10
12
14
16
18
CASE FEMALES CONTROL FEMALES
17 
8 8 
1 
9 
7 
47% 12% 
TOTAL FEMALES
HYPERMETHYLATION
NON-
HYPERMETHYLATION
FREQUENCY
      
 
 
Table 6: Frequency of promoter region hypermethylation of hMLH1 gene in esophageal 
cancer cases vs controls as; Total, Males and Females 
PARAMETER CASE MALE FEMALE CONTROL MALE FEMALE 
TOTAL 50 33 17 20 12 08 
HYPER-
METHYLATION 
28 20 08 03 02 01 
FREQUENCY 56% 60% 47% 15% 16% 12% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
 
 
Figure 15: Frequency (% age) Hypermethylation of promoter region of hMLH1 gene in 
Esophageal Cancer Cases vs Control as; Total, Males and Females 
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4.4 FURTHER AS REGARDING THE AGE FIVE MORE SUB-GROUPS OF UPTO-
39 YEARS, 40-49 YEARS, 50-59 YEARS, 60-69 YEARS, AND ABOVE 70 YEARS 
WERE DESIGNED AND REVEALED THE FOLLOWING DATA 
4.4a. Upto-39 years of age group 
From the data and results it was seen that in this age group, the frequency of 
hypermethylation of promoter region of Mis-Match Repair Gene MutL homolog 1 (hMLH1) 
in cases was 50% (02 out of 04) while in controls 0% (0 out of 2), and also it was found that 
Males of this age group shows same frequency 50% (1 out of 2) Compared to Females 50% 
(1 out of 2), which is shown in histogram in Figure 16 and Data in Table 7. 
4.4b. 40-49 years of age group 
From the results it was seen that 04 cases of this age group shows promoter region 
hypermethylation of hMLH1 Gene out of 06 (66%) while in controls 0 out of 03 (0%) and 
also it was found that Males of this age group shows high frequency 100% (3 out of 3) 
Compared to Females 33% (1 out of 3), which is represented in histogram in Figure 17 and 
Data is Tabulated in Table 8. 
4.4c. 50-59 years of age group 
From the results and data it was seen that 07 cases of this age group shows promoter 
region methylation of hMLH1 gene out of 13 (57%) while in controls 01 out of 05 (20%) and 
the Males of this age group also shows high frequency 63% (5 out of 8) compared to Females 
40% (2 out of 5) of same age group, which is shown in histogram in Figure 18 and data is 
tabulated in Table 9. 
4.4d. 60-69 years of age group 
From the results it was seen that 10 cases out of 20 (50%) of this age group showed 
promoter region hypermethylation of hMLH1 gene while in controls 02 out of 07 (28%) and 
the Males of this age group shows lessor frequency 46% (7 out of 15) compared to Females 
60% (3 out of 5) which is represented by histogram in Figure 19 and data is tabulated in 
Table 10. 
 
      
 
 
4.4e. 70-above years of age group 
From the results it was seen that 05 cases of this age group shows promoter region 
methylation of hMLH1 gene out of 07 cases (71%) while in controls 0 out of 03 (0%) and the 
Males of the above 70 years of age group shows higher frequency 66% (4 out of 5) compared 
to Females 50% (1 out of 2) of same age group, which is represented by histogram in Figure 
20 and data is tabulated in Table 11. 
4.4f. below 40 and above 40 years of age group 
The Frequency of MutL homolog 1 (hMLH1) gene promoter region hypermethylation 
was found high in Esophageal Cancer Cases of above 40 years of age, 26 out of 46 (56%) and 
in controls 03 out of 18 (16%) and was significant as p=0.005 (O.R=6.50 , 95% C.I=1.651-
25.58) compared to below 40 years of age 02 out of 04 (50%) and in controls 0 out of 02 
(0%) and association was insignificant as p=0.4667 (O.R=5.00 , 95% C.I=0.149-166).  
In Case of Males of above 40 years of age hypermethylation frequency was found 
high 20 out of 31(64%) compared to Males of below 40 years of age 01 out of 02 (50%) and 
in case of Females of above 40 years of age 07 out of 15(46%) compared to below 40 years 
of age 01 out of 02(50%).Which is represented by histogram in Figure 21 and data shown in 
Table 12. 
 
 
 
 
 
 
 
 
 
      
 
 
Table 7: Frequency of promoter region hypermethylation of hMLH1 gene in esophageal 
cancer cases vs controls of below 40 years of age as; Total, Males and Females 
PARAMETER CASE MALE FEMALE CONTROL MALE FEMALE 
TOTAL 04 02 02 02 01 01 
HYPER-
METHYLATION 
02 01 01 0 0 0 
FREQUENCY 50% 50% 50% 0% 0% 0% 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
 
 
Figure 16: Frequency (%age) Hypermethylation of promoter region of hMLH1 gene in 
Esophageal Cancer Cases vs Control of below 40 years of age as; Total, Males 
and Females 
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Table 8: Frequency of promoter region hypermethylation of hMLH1 gene in esophageal 
cancer cases vs controls of 40-49 years of age group as; Total, Males and Females 
 
 
 
PARAMETER  
 
CASE 
 
MALE 
 
FEMALE 
 
CONTROL 
 
MALE 
 
FEMALE 
TOTAL 06 03 03 03 02 01 
HYPER-
METHYLATION 
04 03 01 0 0 0 
FREQUENCY 66% 100% 33% 0% 0% 0% 
  
 
 
 
 
 
 
 
 
      
 
 
 
Figure 17: Frequency  (%age ) Hypermethylation of promoter region of  hMLH1 gene in 
Esophageal Cancer Cases vs  Control of 40-49 years of age group as; Total , 
Males and Females 
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Table 9: Frequency of promoter region hypermethylation of hMLH1 gene in esophageal 
cancer cases vs controls of 50-59 years of age group as; Total, Males and Females 
 
PARAMETER  CASE MALE FEMALE CONTROL MALE FEMALE 
TOTAL 13 08 05 05 03 02 
HYPER-
METHYLATION 
07 05 02 01 01 0 
FREQUENCY 57% 63% 40% 20% 33% 0% 
  
 
 
 
 
 
 
 
 
 
 
      
 
 
 
Figure 18: Frequency  (%age ) Hypermethylation of promoter region of  hMLH1 gene in 
Esophageal Cancer Cases vs  Control of 50-59 years of age group as; Total , 
Males and Females 
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Table 10: Frequency of promoter region hypermethylation of hMLH1 gene in 
esophageal cancer cases vs controls of 60-69 years of age group as; Total, Males and 
Females 
 
 
PARAMETER  CASE MALE FEMALE CONTROL MALE FEMALE 
TOTAL 20 15 05 07 04 03 
HYPER-
METHYLATION 
10 07 03 02 01 01 
FREQUENCY 50% 46% 60% 28% 25% 33% 
  
 
 
 
 
 
 
 
 
 
      
 
 
 
Figure 19: Frequency  (%age ) Hypermethylation of promoter region of  hMLH1 gene in 
Esophageal Cancer Cases vs  Control of 60-69 years of age group as; Total , 
Males and Females 
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Table 11: Frequency of promoter region hypermethylation of hMLH1 gene in 
esophageal cancer cases vs controls of 70-years above of age group as; Total, Males and 
Females 
 
 
PARAMETER CASE MALE FEMALE CONTROL MALE FEMALE 
TOTAL 07 05 02 03 02 01 
HYPER-
METHYLATION 
05 04 01 0 0 0 
FREQUENCY 71% 66% 50% 0% 0% 0% 
  
 
 
 
 
 
 
 
 
 
      
 
 
 
Figure 20: Frequency  (%age ) Hypermethylation of promoter region of  hMLH1 gene in 
Esophageal Cancer Cases vs  Control of 70 years above of age group as; Total , 
Males and Females  
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Table 12: Frequency (%age) of Hypermethylation of promoter region of hMLH1 gene 
in Esophageal cancer Cases of Males and Females of below 40 years and above 40 years 
of age as; Total hypermethylation, Male hypermethylation and Female 
hypermethylation 
 
 
PARAMETER  BELOE 40 YRS ABOVE 40 YRS 
 
CASES 
Total 04 46 
Hypermethylation 02 26 
Frequency 50% 56% 
CONTROLS 
Total 02 18 
Hypermethylation 00 03 
Frequency 0% 16% 
 
MALES 
Total 02 31 
Hypermethylation 01 20 
Frequency 50% 64% 
 
FEMALES 
Total 02 15 
Hypermethylation 01 07 
Frequency 50% 46% 
  
 
      
 
 
 
Figure 21: Frequency (%age) of Hypermethylation of promoter region of hMLH1 gene in 
Esophageal cancer Cases of Males and Females of below 40 years and above 
40 years of age as; Total hypermethylation, Male hypermethylation and 
Female hypermethylation 
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DISCUSSION: 
eports indicate that the Kashmir valley of Jammu and Kashmir State of India ranks 
among the highest incidence area for esophageal cancer in the world (Khuroo et al., 
1992). Esophageal cancers are typically carcinomas which arise from the epithelium, or 
surface lining, of the esophagus. Most esophageal cancers fall into one of two classes: 
squamous cell carcinomas, which are similar to head and neck cancer in their appearance and 
association with tobacco and alcohol consumption, and adenocarcinomas, which are often 
associated with a history of gastro esophageal reflux disease and Barrett's esophagus. A 
general rule of thumb is that a cancer in the upper two-thirds is a squamous cell carcinoma 
and one in the lower one-third is an adenocarcinoma (Shield et al., 2005; Halperin et al., 
2008).Injury or irritation to the esophagus is caused by a number of substances and may 
result in esophagitis, GERD, Barrett’s esophagus or esophageal cancer. At the outset, most of 
these conditions exhibit an inflammatory pathology, which may persist as a benign lesion or 
progress to cancer. Nearly 60% of severe grade dysplasias and 5-20% of cases of achalasia in 
the esophagus progress to malignancy (Peracchia et al., 1991; Meijssen et al., 1992). The risk 
of Barrett’s esophagus developing into invasive carcinoma is 40- fold higher than the cancer 
risk of the general population (Cameron et al., 1985). Molecular markers are therefore needed 
to indicate the risk of progression of these inflammatory conditions to more severe diseases 
including malignancy. These markers should also be able to predict the prognosis of cancer, 
so that we can assess survival chances and response to treatment, and plan a suitable 
management regime. Esophageal cancer is one of the least studied and deadliest cancers, with 
a remarkable geographical distribution and a low likelihood of cure. Therefore, the current 
challenges in the management of esophageal cancer are to obtain a better understanding of 
the underlying molecular biological alterations to provide new treatment options.It is well 
known that esophageal carcinogenesis is a multistage and progressive process which includes 
basal cell hyperplasia (BCH), dysplasia (DYS), carcinoma in site (CIS) and advanced 
esophageal carcinoma. A variety of genetic lesions are involved in esophageal 
carcinogenesis, including gene amplifications, loss of heterozygosity (LOH) or homozygous 
deletions, mutations, and chromosomal rearrangements. From the above mentioned genetic 
lesions, mutations are greatly focused on. 
R 
      
 
 
Genetic mutation of genes that inhibit the formation of tumors has long been known 
to be one of the main driving forces in the development of cancer. However, recent data have 
focused our attention to the contribution of epigenetics to tumorigenesis. In tumorigenesis of 
the esophagus, the epigenetic inactivation of genes is as an important a driving force as the 
inactivation of genes by mutation (Enzinger and Mayer 1993; Chen and Yang 2001; 
Momparler 2003). Synergistic effect of dietary, environmental, genetic and microbial factors 
is being associated with the development of esophageal cancer and it has multifactorial 
epidemiology (Zhou and Watanabe 1999; Zhang et al., 2000; Nayar et al., 2000; Shi et al., 
2000; Lagergren et al., 2000; Dhillon et al., 2001). The contributing factors are not the same 
in different populations of the world and a common risk factor is yet to be identified.  
Majority of the esophageal cancer cases are found in developing countries of the world, 
particularly in Asia (Parkin et al., 1988; Shottenfeld, 1984). Kashmir is a known region of 
high incidence of esophageal cancer (Maqbool and Ahad 1974; Jan and Zargar 1988; Khuroo 
1992) and is part of so called “Asian Esophageal cancer belt”. Despite much effort that has 
been done in improving treatment and diagnosis, esophageal cancer prognosis is still poor, 
making it the sixth most fatal malignancy in the world (Parkin et al., 2005). 
DNA methylation in cancer has become the topic of intense investigation. As 
compared with normal cells, the malignant cells show major disruptions in their DNA 
methylation patterns (Baylin and Herman 2000). Hypermethylation involves CpG islands 
whereas Hypomethylation usually involves repeated DNA sequences, such as long 
interspersed nuclear elements (Ehrlich, 2002). Promoter hypermethylation is an alternative 
mechanism of gene inactivation in carcinogenesis (Baylin et al., 1998). Several studies have 
suggested that aberrant methylation of the promoter causes transcriptional silencing of some 
important suppressor genes, such as p16 (Merlo et al., 1995), E-cadherin (Graff et al., 1995), 
and von Hippel Lindau (VHL) gene (Herman et al., 1994), and this has been implicated in the 
carcinogenic process in many cancers (Baylin et al., 1998). 
The hMLH1 protein, a mismatch repair enzyme, maintains the fidelity of the genome 
during cellular proliferation. It has no known enzymatic activity and probably acts as a 
‘molecular matchmaker’, recruiting other DNA-repair proteins to the mismatch repair 
complex (Modrich, 1991). Dysfunction of a mismatch repair system such as hMLH1 and 
hMSH2 could alter microsatellites, short tandem repetitive sequences (Thibodeau et al., 
1993). The mismatch repair system is composed of a highly diverse group of proteins that 
interact with numerous DNA structures during DNA repair and replication (Hoffmann and 
      
 
 
Borts 2004). Mismatch repair (MMR) plays a central role in maintaining genomic stability by 
repairing DNA replication errors and inhibiting recombination between non-identical 
sequences (Jacob and Praz 2002; Duval and Hamelin 2002). Loss of mismatch repair causes 
destabilization of the genome and results in high mutation frequency (Loukola et al., 2001). 
hMLH1 gene is a prominent component in the human mismatch repair system and its 
dysfunction is involved in a number of patients with HNPCC (Han et al., 1995; Hutter et al., 
1995). It has been reported that germline mutations of MMR are identified in nearly 80% of 
the patients with HNPCC and almost 60% of the mutations are in hMLH1 (Peltomaki and 
Vasen 1997). Reports of hypermethylation in cancer far outnumber the reports of 
hypomethylation in cancer. There are several protective mechanisms that prevent the 
hypermethylation of the CpG islands. These include active transcription, active 
demethylation, replication timing, and local chromatin structure preventing access to the 
DNA methyltransferase (Clark and Melki 2002). To date, Nearly 50% of numerous genes 
have been found to undergo hypermethylation in cancer. The genes that are susceptible are 
the genes involved in cell cycle regulation (p16INK4a, p15INK4a, Rb, p14ARF) genes 
associated with DNA repair (hMLH1,BRCA1, MGMT), apoptosis (DAPK, 
TMS1),angiogenesis (THBS1, VHL),),invasion (CDH1, TIMP3)  ,drug resistance, 
detoxification, differentiation, and metastasis (Jones and Baylin 2002). 
Considering the important role of promoter methylation in inactivation of hMLH1 
which is one of the frequently altered genes in carcinoma of esophagus and many other 
human cancers, in the present study, we investigated the level of hMLH1 promoter 
methylation in esophageal carcinoma tissues of patients from Kashmir valley where 
frequency is higher as compared to other regions of India. Cancer and some chronic 
inflammatory conditions have been associated with genomic instability (Ishitsuka et al., 
2001; Gao et al., 2005). The MMR system maintains genomic integrity, and it is accepted 
that defects in MMR genes are responsible for the microsatellite instability (MSI) observed in 
different diseases (Brentnall et al., 1995; Lynch and Hoops 2002). Approximately 27% of 
esophageal tumors deficient in hMLH1 repair gene expression have been associated with MSI 
(Hayashi et al., 2003). It was also observed hMLH1 hypermethylation to be associated with 
MSI in about 42% of esophageal cancers (Vasavi and Hasan Q).MMR gene silencing has 
been reported in several cancers and inflammatory conditions such as inflammatory bowel 
disease, head and neck cancers, and cancers of the GI tract (Wang et al. 2001; Bubb et al., 
1996; Kang et al., 2002). In most of these studies, immunohistochemistry and mRNA 
      
 
 
expression analysis showed the absence of hMLH1 protein; however, no mutations were 
found to be responsible for this (Kane et al., 1997; Liu et al., 1995). Epigenetic silencing 
through promoter methylation of the hMLH1 repair gene was associated with loss of hMLH1 
protein expression (Razin et al., 1980; Kane et al., 1997). In esophageal cancers, there are 
controversial reports regarding the association of hypermethylation with hMLH1 gene 
silencing (Hayashi et al., 2003; Nie et al., 2002). Esophageal cancers have been associated 
with late diagnosis and poor prognosis. 
In this study it was attempted to identify in individuals with esophageal cancer 
whether the altered methylation status of promoter region of Mismatch Repair (hMLH1) gene 
could be used as a molecular marker associated with esophageal carcinogenesis. For the first 
time such a study was conducted regarding this Mismatch Repair (hMLH1) gene as related to 
esophageal cancer in the population of Kashmiri origin. To determine the status of Mismatch 
Repair (hMLH1) gene promoter methylation in Esophageal Cancer Cases from the population 
of Kashmiri origin, we performed Methylation Specific Polymerase chain reaction for 
hMLH1 gene in 50 surgically resected esophageal cases and compared with that of 20 
histopathologically confirmed normal tissues. The Study included 33 Male Cases and 17 
Female Cases out of which only 04 Cases were below the age of 40 years and remaining 46 
Cases were above the age of 40 years and Controls include 12 Males and 08 Females out of 
which 02 Controls were below the age of 40 years and remaining 18 Controls were above the 
age of 40 years. 
Figure 10 and 11 shows examples of MS-PCR results. The frequency of promoter 
hypermethylation was 56% (28 out of 50) for hMLH1 gene in Cases. Among the 50 cases, 
less than a half exhibited amplifications with methylated primer only (<50%). In other hand, 
for some Cases, we observed amplifications with both methylated as well as unmethylated 
primers, this can be probably explained by the presence of infiltrating lymphocytes and/or 
non-malignant epithelial cells in the primary tumors. When we reviewed the literature, the 
methylation frequency ranged from 8 to 50% for hMLH1 (Hayashi et al., 2003; Geddert et 
al., 2004; Nie et al., 2002). The higher percentage of hMLH1 promoter hypermethylation 
seen in the present study may be because of the difference in type of sample used, promoter 
region assessed and/or technique employed. In earlier studies conducted by Geddert et al., 
2004; Hayashi et al., 2003; Nie et al., 2002, paraffin-embedded tissue material was used, 
while in the present study we employed fresh biopsy specimens. Wang et al., 2003 reported a 
higher percentage of hMLH1 hypermethylation with HpaII-based PCR methylation assay 
      
 
 
when compared with methylation- specific PCR, which involves bisulfite pre-treatment of 
DNA.The lower methylation reported in these earlier studies compared with our study may 
be due to the techniques employed. 
From the results and data It was observed that 28 out of 50 (56%) of the esophageal 
Cases showed bright bands in methylated (M) lane and diminished or no bands in 
unmethylated (U) lane which confirms hMLH1 gene promoter is methylated (Figure 10). 
However 22 out of 50 (44%) of the cases showed  no bands in methylated (M) lane and bright 
bands in unmethylated (U) lane which confirms hMLH1 gene promoter is not methylated  
(Figure 10). In case of normal esophageal controls 17 out of 20 (85%) of the esophageal 
controls showed no bands in methylated (M) wells and bright bands in unmethylated (U) 
wells which confirms hMLH1 gene promoter is not hypermethylated (Figure 11 control 18, 
06 and 08) while in remaining 03 controls, bands were seen in methylated (M) wells as well 
as in unmethylated wells which confirms that remaining 15% of normal esophageal controls 
were hypermethylated (Figure 11 control 67). Statistically the association of promoter region 
hypermethylation of mismatch repair gene (hMLH1) with esophageal cancer was evaluated 
using χ2-test (chi-square test) with odds ratio and was found significant (p=0.0028, odds 
ratio=7.2121 and 95% C.I=1.822-27.79). It was also found that the methylation status of 
MutL homolog 1 (hMLH1) gene in esophageal cancer cases was high in Males (60%) 
compared to Females (47%) and in Controls, Males (16%) also shows high with respect to 
Females (12%) which shows insignificant association as  p=0.3827,odds ratio=1.7310 and 
95% C.I=0.5312-5.639.From the data it was concluded that the Frequency of MutL homolog 
1 (hMLH1) gene promoter region hypermethylation was found high in Esophageal Cancer 
Cases of above 40 years of age, 26 out of 46 (56%) and in controls 03 out of 18 (16%) and 
was significant as p=0.005 (O.R=6.50 , 95% C.I=1.651-25.58) compared to below 40 years 
of age 02 out of 04 (50%) and in controls 0 out of 02 (0%) and association was insignificant 
as p=0.4667 (O.R=5.00 , 95% C.I=0.149-166)  and was evaluated by Fishers exact test. 
This study on Esophageal Cancer showed that more than 50% tissues expressed 
methylated hMLH1 promoter. When compared with hMLH1 methylation data available from 
other high prevalent regions such as China, Japan, and Iran, the results were comparable with 
the disease prevalence. Methylation levels were much higher in Caspian littoral of Iran where 
the prevalence of esophageal cancer is higher than what is in Kashmir or other regions of 
China and Japan. 
      
 
 
CONCLUSION: 
his study has interestingly revealed that promoter region hypermethylation status of 
mismatch repair gene hMLH1 shows a significant increase in esophageal cancer 
patients of Kashmiri origin as compared to controls. This became more apparent when the 
data for hypermethylation  was interpreted taking gender into consideration here it was seen 
that males shows higher frequency of promoter region hypermethylation as compared to 
females which was earlier reported in literature and also patients of above 40 years of age 
shows high frequency compared to below 40 years of age. 
Esophageal carcinogenesis is a stepwise process of the accumulation of genetic and 
epigenetic abnormalities. It is clear that promoter hypermethylation of TSGs is as important 
for this multistep process as genetic changes in the progression of esophageal carcinogenesis. 
Our study has supplemented the steadily growing list of genes inactivated by promoter 
hypermethylation in esophageal carcinoma , these provide not only new insights into the 
molecular basis of the diseases but also list of interesting candidate genes for the 
development of molecular markers which might contribute to the improvement of diagnosis 
and also prognosis. In addition, the fact that methylation can be reversed in vitro and the 
effect of the demethylating agent 5-aza-2ʹ-deoxycytidine in vitro raise hope for new treatment 
strategies for esophageal cancer patients. Furthermore, understanding of the significance of 
aberrant DNA methylation in the precancerous stage may show that a new strategy, 
correction of aberrant DNA methylation, can prevent esophageal cancer in people with 
premalignant lesions, such as Barrett’s esophagus, basal cell hyperplasia (BCH) and 
dysplasia (DYS). 
Observing similar level of hMLH1 promoter hypermethylation in patients with 
Esophageal Cancer in this high risk region and comparing it with other parts of the world 
could support the hypothesis that a common molecular mechanism might be involved in 
tumorigenesis of Esophageal Cancer. 
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APPENDIX: 
CHEMICALS AND REAGENTS 
Chemicals: 
Chemical Name Company 
Absolute ethanol BENGAL CHEMICALS 
Acetone GALAXO LABORATORIES 
Agarose MP BIOMEDICALS 
Ammonium  chloride BDH 
Ammonium acetate BDH 
Bromophenol blue SARABHAI  M  CHEMICALS 
Chloroform THOMAS BAKERS 
De Ionized water ALFA LABORATORIES 
Ethedium bromide SRL 
Ethyl acetate MERCK 
Ethylene diamine tetra acetate LOBA CHEMIE 
Formaldehyde GALAXO LABORATORIES 
Glacial acetic acid MERCK 
Hydrochloric acid S D FINE CHEMICALS 
Hydrogen peroxide MERCK 
8-Hydroxyquinoline CDH 
Isoamyl alcohol BDH 
Isopropanol THOMAS BAKERS 
Magnesium chloride MERCK 
Methanol SARABHAI  M  CHEMICALS 
Phenol  SRL 
Potassium acetate QUALGENS 
Potassium bicarbonate QUALGENS 
Potassium chloride LOBA- CHEMIE 
Potassium hydroxide S D FINE CHEMICALS 
2-Propanol MERCK 
Sodium acetate SARABHAI  M  CHEMICALS 
Sodium azide LOBA CHEMIE 
Sodiun bisulphate LOBA CHEMIE 
      
 
 
Sodium carbonate FIZMERCK 
Sodium chloride MERCK 
Sodium dodecyl sulphate MP BIOMEDICALS 
Sodium hydroxide HEMEDIA 
Sodium hydrogen carbonate LOBA- CHEMIE 
Sodium phosphate dibasic LOBA- CHEMIE 
Sodiun thiosulfate LOBA CHEMIE 
Sucrose QUALGENS 
Sulfuric acid MERCK 
TE buffer SRL 
Tris base SIGMA CHEMICAL COMPANY 
Tris HCL HIMEDIA 
Triton X 100 S D FINE CHEMICALS 
Enzymes: 
 
Taq polymerase FERMENTAS /  BIOTOOLS 
Proteinase K ZYMO RESEARCH 
MISCELLANEOUS  MATERIAL: 
 
100bp DNA ladder FERMENTAS / BIO ENZYME 
PCR  Reagents: 
 
10 X Buffer (with Mgcl2) BIOTOOLS 
dNTPs  CINNAGEN 
Primers (methylated and  unmethylated) GENESCRIPT 
Universal Methylated Human DNA 
Standard and Control with primers 
ZYMO RESEARCH 
DNA Isolation: 
DNA was iosolated by kit based method. The kit used was Quick- g DNA
TM 
MiniPrep 
supplied by ZYMO RESEARCH. The protocol followed was as directed by the company. 
DNA storage buffer: 
0.5 M EDTA        0.01 ml 
1 M Tris        0.5 ml 
Final volume was made 50 ml with sterile distilled water. 
      
 
 
DNA Bisulfite Modification: 
DNA was modified by kit based method, the kit used was EZ DNA Methylation
TM
 Kit 
supplied by ZYMO RESEARCH. The protocol followed was as directed by the company. 
Reagents for Agarose Gel Electrophoresis: 
Agarose 1%:                  
Agarose        0.5g 
Buffer         50ml 
EtBr         10µl 
Agarose was dissolved in a buffer and heated till a clear solution is formed. EtBr was then 
added to the solution during its cooling just before being poured into the casting tray. 
Bromophenol Blue: 
Bromophenol Blue       0.4g 
Sucrose        20.og 
Bromophenol blue was dissolved in 100ml of distilled water. 
From the above stock solution 31.25ml was taken and sucrose was added. Final volume was 
made 50ml with distilled water. 
Ethedium Bromide: 
Ethedium bromide       10mg 
Ehedium Bromide was dissolved in 1ml of distilled water. The solution was stored in a dark 
bottle at 4˚C. 
50X TAE (pH 8.0) Stock Solution: 
Tris base        242g 
0.5M         100ml 
Glacial acetic acid       57.1ml 
Final volume was made 1000ml with distilled water. This is stock solution. 
1X TAE (pH 8.0) Working Solution: 
50 X TAE        20ml 
Final volume was made 1000ml with distilled water. 
 
 
      
 
 
 
Reagents for PCR: 
Stock: 
Deoxy ribose nucleotide triphosphate (dNTP) 100mM each dATP, dGTP, dCTP and dTTP. 
Taq polymerase (5U/ml ) 
10X Taq buffer  (16 mmol/L ammonium sulfate, 67 mmol/L Tris- HCL, pH 8.8, 10 mmol/L 
2-mercaptoethanol), 6.7 mmol/ L MgCl2) 
Primers: 100pM in sterile deionised water (Genescript)  
100bp DNA ladder (0.5µg/µl) 
 
 
